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ABSTRACT
GDF1 AS A REGULATOR OF CERAMIDE METABOLISM AND HEMATOPOIESIS
IN ACUTE MYELOID LEUKEMIA
by
Weiyuan Wang
University of New Hampshire

Acute myeloid leukemia (AML) is cancer of the myeloid lineage of blood cells. In AML,
hematopoietic precursors acquire mutations or chromosomal changes that cause differentiation
arrest. This results in an uncontrolled proliferation of these malignant cells in the bone marrow
that can interfere with normal blood cell production. AML progresses rapidly and can be fatal
within weeks if left untreated. The only current curative treatment is bone marrow transplant,
which has potentially life-threatening side effects. Thus, a better understanding of the underlying
biology of AML is needed to enable the development of better therapeutic modalities.
Ceramides are a family of wax-like lipids in the broader category of sphingolipids.
Ceramide is comprised of a sphingoid base linked to a fatty acid through an amide group.
Recently, ceramides have been appreciated for their bioactive functions including as regulators
of apoptosis. This is significant because ceramide metabolic routes persist in AML that may be
exploited for therapeutic development. Recently, it was shown that nanoliposomal C6-ceramide
(Lip-C6) exerts unique therapeutic efficacy towards AML with myelodysplastic syndromerelated changes (AML-MRC). In contrast, other forms of AML were resistant to Lip-C6 due to
enhanced ceramide metabolism. Interestingly, in these Lip-C6-resistant AMLs the gene encoding
for growth/differentiation factor 1 (GDF1) is downregulated. GDF1 is encoded from a rare
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bicistronic gene that also encodes for ceramide synthase 1. GDF1 is presently only appreciated to
have roles in embryonic and cardiac development. However, its genetic link to a ceramide
biosynthesizing enzyme as well as its inverse relation to Lip-C6-resistant AML suggest that it
may also exert a role in ceramide metabolism.
This dissertation research first explored a hypothesis that GDF1 regulates ceramide
detoxification in AML. GDF1 expression was variably expressed across AML subtypes but was
mostly downregulated in Lip-C6-resistant AML. Moreover, there was an inverse relationship
between GDF1 expression and genes encoding for ceramide neutralizing enzymes. This inverse
relationship was validated as treatment of AML cell lines with recombinant GDF1
downregulated the expression of these same genes. Interestingly, recombinant GDF1 was also
able to uniquely promote SMAD2/3 phosphorylation while concurrently downregulating STAT2
tyrosine phosphorylation in a transforming growth factor beta receptor 1 (TGFbR1)-dependent
manner. Next, this dissertation research evaluated the ability of GDF1 to regulate hematopoiesis
and exert an anti-AML therapeutic effect. Recombinant GDF1 restored hematopoiesis and
promote erythropoiesis (red blood cell development) both in vitro and in vivo. GDF1 was unable
to impact hematopoiesis in normal bone marrow, suggesting that its hematopoietic-regulatory
therapeutic effect was specific to abnormal and malignant situations. Furthermore, GDF1
treatment exerted combinatorial anti-AML efficacy with cytarabine and extended the overall
survival of mice engrafted with a highly aggressive AML. The final aspect of this dissertation
studied a novel transgenic obese AML mouse model to evaluate links between obesity and AML.
Obesity provokes profound changes in lipid homeostasis including by upregulating sphingolipid
biosynthesis. Transgenic obese AML mice developed a robust leukemia burden compared with
non-obese counterparts. More so, genes responsible for regulation of the ceramide-mediated
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NADPH oxidase 2 were upregulated in these transgenic obese AML mice. This demonstrated a
further sphingolipid-mediated dysfunction that can contribute to the development and
progression of AML.
Overall, this dissertation research has uncovered important sphingolipid metabolic
biology that underlies the development and progression of AML. This has revealed pathways
associated with resistance to ceramide-elevating therapeutics such as Lip-C6. Most noteworthy,
this research has identified for the first time an ability for GDF1 to regulate ceramide
metabolism, hematopoiesis, and erythropoiesis. It has also shown that GDF1 can exert effects
through a unique TGFbR1-dependent mechanism regulating both SMAD2/3 and STAT3
signaling. Collectively, this has revealed an anti-AML therapeutic ability for GDF1 linked to the
regulation of ceramide metabolism.
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CHAPTER 1

INTRODUCTION

1.1. Influences on the Hematopoietic Stem Cell Niche1

Hematopoietic stem cells (HSCs) are rare, self-renewing and multipotent progenitors that
sustain hematopoiesis throughout the lifespan (Crane et al., 2017). This process involves a
complex variety of interactions with supporting cells and ultimately generates all types of blood
cells, including erythrocytes, platelets, and leukocytes. In this process, HSCs first give rise to an
array of hematopoietic stem progenitors which have restricted self-renewing capacity before
terminal differentiation into mature cells, such as erythrocytes, megakaryocytes that produce
platelets, and leukocytes. In homeostasis, HSCs are mostly in a dormant state, striking a
remarkable balance between quiescence and self-renewal. But in cases of hematopoietic stresses
such as severe infection or blood loss, HSCs activate to regenerate hematopoietic cells.
HSCs normally reside in the bone marrow within the medullary cavities of long bones
and axial bones, although they can transiently expand into facultative niches in extramedullary
tissues such as the liver and the spleen under severe hematopoietic stresses (Crane et al., 2017).
The bone marrow microenvironment provides signals for the maintenance and regulation of
HSCs, directing proliferation, apoptosis, extra-medullary mobilization, and quiescence (Geiger et
al., 2013). In the past decade, advancements in imaging, HSC biomarker discovery, and
improvement in functional genomic techniques have allowed for a deeper understanding of the
1

Weiyuan Wang, Timothy J. Brown, and Brian M. Barth. Influences on the Hematopoietic Stem Cell Niche.
Submitted to Critical Reviews in Oncology/Hematology on September 6, 2020.
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mechanisms within the bone marrow microenvironment that regulate HSCs. This review will
summarize the current understanding of the adult hematopoietic bone marrow
microenvironment, focusing on cellular and molecular participants and their contributions to
normal HSC regulation, as well as the crosstalk between the niche and HSCs in malignant
transformation.

The HSC niches
Human bone marrow is located within the trabecular region of the large bones, which is
lined by the endosteum, formed by osteoblasts (Calvi and Link, 2014; Wang et al., 2013a). This
tissue is highly vascularized and rich in micro vessels and capillaries (Nombela-Arrieta et al.,
2013; Wang et al., 2013a). In the center of the bone marrow, longitudinal large arteries give rise
to smaller radical arteries, which then branch into arterioles. Arterial circulation transitions to
venous circulation near the endosteal surface. The network of arterial vessels progressively
transforms into wider, irregularly shaped sinusoids which eventually coalesce into a big
collecting central sinus and drain into the venous circulation (Nombela-Arrieta et al., 2013;
Wang et al., 2013a).
Within the bone marrow, local tissue microenvironments with a distinct cellular and
molecular makeup, termed “niches”, maintain and regulate HSCs (Morrison and Spradling,
2008). The bone marrow is a complex cellular environment with HSCs residing in close contact
with multiple cell types, including perivascular mesenchymal stromal cells and endothelial cells
(Ehninger and Trumpp, 2011; Morrison and Spradling, 2008; Nombela-Arrieta et al., 2013;
Wang et al., 2013a). These cells secrete growth factors and chemokines that participate in normal
hematopoiesis and support progenitor cells. Confocal imaging and spatial modelling studies have

2

confirmed that HSCs are widely distributed throughout the bone marrow. In addition, they are
more common at the periphery of the marrow near the bone surfaces compared to the medullary
regions of the bone, and in the metaphysis of the bone (Acar et al., 2015) (Figure 1.1). In these
niches, approximately 80% of HSCs reside adjacent to sinusoidal blood vessels in the bone
marrow; the remainder are mainly associated specifically with arterioles or adjacent to transition
zone vessels in the endosteal region (Crane et al., 2017; Nombela-Arrieta et al., 2013; Spencer et
al., 2014; Wang et al., 2013a).

3

Figure 1.1. Schematic representation of the HSC niche. The bone marrow microenvironment is
composed of different cell populations that coordinately contribute to the regulation of HSCs. These
include perivascular stromal cells, endothelial cells, megakaryocytes, sympathetic neurons and nonmyelinating Schwann cells, adipocytes, monocytes and macrophages. The arteriolar niche has a higher
ratio of quiescent HSCs, whereas majorities of both quiescent and cycling HSCs localize to the sinusoidal
niche. The absolute pO2 of the bone marrow is quite low despite very high vascular density, with the
lowest pO2 in perisinusoidal regions. The endosteal region, by contrast, is less hypoxic as it is perfused
with small arteries.

4

Growth factors that modulate HSC function
The normal function of HSCs is supported by cells that reside within the bone marrow
niche. These supporting cell types that are responsible for the production of growth factors are
known to be required for HSC maintenance, including C-X-C motif chemokine 12 (CXCL12),
stem cell factor (SCF) and thrombopoietin (THPO) (Crane et al., 2017). Other factors in the bone
marrow may also modulate HSC function in a non-cell-autonomous way by promoting
hematopoietic regeneration after injury, although they are not necessarily required for HSC
maintenance or hematopoiesis.

C-X-C motif chemokine 12 (CXCL12)
CXCL12, also known as stromal cell-derived factor 1, is a chemokine protein
ubiquitously expressed in many tissues and cell types that functions as an HSC homing signal to
the marrow (Calvi and Link, 2014). In the bone marrow, CXCL12 is constitutively expressed at
high levels by perivascular stromal cells. When deleted from mice, absence of CXCL12 is
universally fatal shortly after birth (Hoffman and Calvi, 2014). Its receptor, CXCR4, is mainly
expressed on immature and mature hematopoietic cell types. This CXCL12/CXCR4 signaling
closely regulates HSC retention and maintenance in bone marrow niches (Katayama et al., 2006;
Lai et al., 2014; Walenkamp et al., 2017). Disruption of this connection leads to release of HSCs
into the peripheral blood with limited effect on the function of HSC (Calvi and Link, 2014;
Spiegel et al., 2008). Additionally, depletion of bone marrow macrophages reduces CXCL12
expression in the bone marrow and promotes HSC mobilization and extramedullary
hematopoiesis (Chow et al., 2011). Similarly, deletion of Cxcl12 from arteriolar Neuron-glial
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antigen 2 (NG2)-expressing cells results in HSC reductions and altered HSC localization within
the bone marrow (Asada et al., 2017).
This signaling is also vital for subsequent repopulation of HSCs in the bone marrow (Lai
et al., 2014). Deletion of Cxcr4 in adult mice resulted in severe reduction of HSC numbers and
increased sensitivity to myelotoxic injury (Sugiyama et al., 2006). Deletion of Cxcl12 from
perivascular stromal cells or endothelial cells depletes HSCs from the bone marrow. In contrast,
conditional deletion of Cxcl12 from osteoblasts in murine lines leads to loss of lymphoid
progenitors but had little or no effect on the number of HSCs (Birbrair and Frenette, 2016; Ding
and Morrison, 2013). Despite this, mice with deletion of Cxcl12 maintain normal levels of B-cell
and T-cell progenitors (Hoffman and Calvi, 2014). However, ablation of osteoblasts eventually
results in pancytopenia, likely implicating an indirect regulation of HSCs by osteoblasts (Ding et
al., 2012; Morrison and Scadden, 2014; Visnjic et al., 2004). Indeed, proximal osteolineage cells
upregulate genes encoding cell surface and immune response proteins, such as CXCL12 and
vascular cell adhesion molecule 1 (VCAM-1), providing a possible mechanism by which
osteoblasts can regulate HSCs. However, their exact function in hematopoiesis is incompletely
understood (Birbrair and Frenette, 2016; Silberstein et al., 2016).

Stem cell factor
SCF, also known as KIT ligand, is a growth factor that is required for HSC maintenance.
In the bone marrow, SCF is primarily expressed by perivascular and endothelial cells in
proximity to cells that also express CXCL12 (Birbrair and Frenette, 2016; Ding et al., 2012;
Morrison and Scadden, 2014). It activates signaling by the c-KIT receptor tyrosine kinase, which
is widely expressed on HSCs and mast cells (Ho et al., 2017; Ogawa et al., 1991). SCF is present
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in both membrane-bound and soluble forms (Crane et al., 2017). HSCs are depleted in Sl/Sld
mutant mice, which lack membrane-bound SCF but express the soluble form (Barker, 1994).
This indicates that the membrane bound SCF is more important for HSC maintenance.
Endothelial and leptin receptor-expressing perivascular stromal cells are the major sources of
SCF for HSC maintenance in normal adult bone marrow (Ding et al., 2012). Deletion of Scf from
each cell population has additive effects on HSC depletion. HSCs are depleted from bone
marrow when Scf is deleted from either endothelial cells or leptin receptor-expressing
perivascular stromal cells (Ding et al., 2012). In this scenario, adipocytes have the capacity to
synthesize SCF to maintain the HSC population (Zhou et al., 2017). In fact, adipocytes in the
long bones promote hematopoietic recovery through production of SCF after irradiation (Zhou et
al., 2017). In contrast, HSC frequency or function was not affected by conditional deletion of Scf
from osteoblasts, hematopoietic cells, or perivascular mesenchymal stem cells (MSCs) (Ding et
al., 2012).

Thrombopoietin
THPO is mostly produced by the liver and kidneys, in addition to the bone marrow
stroma, and it to a much lesser extent is critically involved in the maintenance of adult quiescent
HSCs (de Graaf and Metcalf, 2011; Morrison and Scadden, 2014; Qian et al., 2007; Yoshihara et
al., 2007). Unlike other hormones, THPO is not negatively regulated; rather it is directly
regulated by platelet quantities (de Graaf and Metcalf, 2011; Morrison and Scadden, 2014; Qian
et al., 2007; Yoshihara et al., 2007). In its normal state, THPO produced by the liver promotes
megakaryocyte growth, migration and platelet production (Khodadi et al., 2016). Secreted THPO
binds to the THPO receptor, which is also known as the myeloproliferative leukemia protein
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(MPL), and activates a signaling cascade that results in megakaryocyte maturation within the
marrow (Khodadi et al., 2016). Maturing megakaryocytes within the marrow interact with
numerous cells, including osteoblasts, osteoclasts, HSCs, and plasma cells (Khodadi et al.,
2016). Loss of THPO or THPO signaling results in amegakaryocytic thrombocytopenia and
eventually progresses to bone marrow failure via loss of HSC quiescence (Decker et al., 2018;
Qian et al., 2007; Yoshihara et al., 2007). Murine THPO-knockout models have demonstrated
that absence of THPO results in failure to reconstitute marrow cellularity following irradiation
(Decker et al., 2018). Further, liver-specific deletion of murine Thpo reduces both marrow
megakaryocytes and HSCs without decreasing the overall marrow cellularity, implicating THPO
as a critical factor in the maintenance of HSCs (Decker et al., 2018). THPO ensures HSC
chromosomal integrity and function in response to irradiation by regulating the DNA-damage
response (de Laval et al., 2014). THPO receptor agonists drive HSCs into self-renewing
divisions, leading to quantitative expansion of functional HSC (Geiger et al., 2013). Further,
depletion of megakaryocytes results in a loss of HSC quiescence and increases the expansion of
HSCs, likely by a concomitant increase in THPO-signaling (Bruns et al., 2014, 2014). In ex vivo
models, supplementation of HSC cultures with THPO results in accelerated expansion of HSCs
(de Graaf and Metcalf, 2011).
Indeed, during times of hematopoietic distress in which THPO signaling may be
enhanced, such as during periods of thrombocytopenia or during treatment with THPO-mimetics
such as eltrombopag and romiplostim, HSCs exit their quiescent phase and begin to divide
through an myeloproliferative leukemia-mediated mechanism (Kovtonyuk et al., 2016).
However, long term increases in THPO or treatment with THPO-mimetics results in bone
marrow fibrosis through transforming growth factor-beta (TGFb), platelet-derived growth factor,
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and mechanisms resulting in increased bone marrow reticulin production (Khodadi et al., 2016;
Kuter, 2009). THPO-mediated marrow fibrosis may be reversible upon normalization of THPO
levels or cessation of therapy with THPO-mimetics (Kuter, 2009).

Angiogenin
Angiogenin is a secreted ribonuclease with a broad range of effects, including
angiogenesis, neurogenesis, and immune regulation (Yoshihara et al., 2007). In HSCs,
angiogenin promotes quiescence, but it promotes proliferation in lineage-committed myeloid
progenitors; the exact mechanism is not yet understood (Yoshihara et al., 2007). Angiogenin is
expressed at a higher level in mesenchymal progenitors, osteolineage-committed progenitors,
and periarteriolar sheath cells. It restricts the proliferation of early lymphoid progenitors and
HSCs, thereby promoting HSC self-renewal and repopulating potential (Qian et al., 2007).
Supplemental therapy with angiogenin promotes hematopoietic regeneration following bone
marrow failure in stem cell transplantation, while deletion of angiogenin from those cells
resulted in an increased number of long-term HSCs and more active cycling of HSCs (Yoshihara
et al., 2007).

Granulocyte colony stimulating factor (G-CSF)
G-CSF is a cytokine that is mainly produced by the endothelium and macrophages. It is
clinically used to promote HSC mobilization into the bloodstream and to increase the production
of granulocytes, either to reconstitute a depleted immune system or to prepare a patient for a
bone marrow donation. To promote mobilization, G-CSF suppresses the expression of CXCL12
from marrow stromal cells, downregulating the homing signal that attracts HSCs to the marrow
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niche while upregulating CXCR4 (Calvi and Link, 2014; Hoffman and Calvi, 2014).
Interestingly, activating osteoclasts via administration of receptor activator of nuclear factor
kappa-Β-ligand results in mobilization of HSCs, but inhibition of osteoclasts with calcitonin
mitigates the G-CSF-induced mobilization of HSCs (Calvi and Link, 2014). It has been
hypothesized that activated osteoclasts secrete cathepsin K which may cleave CXCL12 and
result in mobilization of HSCs (Calvi and Link, 2014). Further, neutrophils are believed to play a
role in G-CSF-mediated HSC mobilization, although this too is incompletely understood (Calvi
and Link, 2014). Recently, it was found that these two functions induced by G-CSF work
independently. While cells with limited regenerative potential are induced to repopulate by GCSF, dormant HSCs are only mobilized into the blood without any proliferation (de Graaf and
Metcalf, 2011).

Bone marrow niche cells that regulate HSCs
The HSC niche can be regulated by various types of cells, including perivascular stromal
cells and endothelial cells, which can produce factors including CXCL12 and SCF. Several other
cell types also contribute to maintenance of the HSC niche and can leverage additional factors
including CXCL4, G-CSF, and TGFβ (Ehninger and Trumpp, 2011).

Bone marrow stromal cells
CXCL12-abundant reticular cells reside in the marrow at sites closely associated with
HSCs (Hoffman and Calvi, 2014). They have been found to largely overlap with nestin-GFP+
stromal cells and leptin receptor-expressing cells in studies where both are defined by transgenic
expression using defined stromal-specific promoters (Anthony and Link, 2014; Ding et al., 2012;
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Nagasawa et al., 2011; Omatsu et al., 2010; Sugiyama et al., 2006). These stromal cells are all
MSCs that have both adipogenic and osteogenic potential. They differentiate into adipocytic and
osteoblastic mesenchymal lineages in the adult bone marrow, producing large amounts of
proteins for the storage of nutritional energy or bone formation (Nagasawa et al., 2011; Omatsu
et al., 2010; Zhou et al., 2014). HSCs are depleted from the bone marrow when Scf or Cxcl12 are
conditionally deleted from leptin receptor-expressing CXCL12-abundant reticular cells. This
implicates them in a maintenance role for the HSC niche (Asada et al., 2017; Ding et al., 2012;
Zhou et al., 2014).

Osteoblasts
It was previously believed that osteoblasts do not directly promote HSC maintenance as
they do not express the crucial niche factors (Ding et al., 2012; Morrison and Scadden, 2014).
However, evidence that osteoblast ablation eventually causes pancytopenia has led to the
hypothesis that osteoblasts indirectly regulate HSCs, likely via crosstalk (Visnjic et al., 2004).
Recently, stable genome-wide transcriptional differences have been identified by single-cell
RNA-seq and transcriptional comparison between HSC-proximal stromal cells and osteolineage
cells either in proximity to transplanted HSCs or at a distance. Proximal osteolineage cells
displayed a significant upregulation of genes encoding cell-surface proteins and those involved
in immune response, such as CXCL12, VCAM-1, and angiogenin, lending further support for
osteoblastic regulation of HSCs (Silberstein et al., 2016).
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Adipocytes
Bone marrow-resident adipocytes are abundant, and their population size increases with
age (Anthony and Link, 2014). Adipocytes have been shown to negatively affect HSC
maintenance, and are increasingly present after chemotherapy and radiation (Naveiras et al.,
2009). Recently, bone marrow adipocytes were found to also synthesize SCF after depletion of
endothelial cells and leptin receptor-expressing stromal cells (Zhou et al., 2017). Despite being
an important source of SCF in both locations, adipocytes in long bones promote hematopoietic
recovery after irradiation, while in caudal vertebrae they inhibit hematopoietic regeneration.
Importantly though, adipogenesis can promote initial hematopoietic recovery following
irradiation (Zhou et al., 2017). This is in accordance with the finding that adipocyte-rich bone
marrow has decreased numbers of HSCs compared with adipocyte-poor bone marrow (Naveiras
et al., 2009).

Endothelial cells
Endothelial cells lining the blood vessels of the bone marrow are also indispensable for
HSC maintenance through producing niche factors CXCL12 and SCF and are a central
component in the maintenance of these cells (Crane et al., 2017; Ding and Morrison, 2013; Ding
et al., 2012; Greenbaum et al., 2013). Despite the relatively small amount of CXCL12 and SCF
expressed, conditional deletion of Cxcl12 or Scf from endothelial cells has been shown to lead to
a decrease in the number of HSC in bone marrow (Ding et al., 2012, 2012). HSC frequency and
function were not affected when Scf was conditionally deleted from other cells types such as
osteoblasts, megakaryocytes or other hematopoietic cells (Ding et al., 2012). The HSC niche thus
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depends on SCF or CXCL12 that is produced by endothelial cells and leptin receptor-expressing
stromal cells.

Neuronal cells
Bone marrow is highly innervated (Katayama et al., 2006). Sympathetic nervous fibers
generally run alongside arterioles, yet subsets are also found in the sinus wall and the
hematopoietic parenchymal tissue, indicating existence of an interconnected network (Giles et
al., 2016). The nervous system is not required for the maintenance of HSCs in the bone marrow
but is critical for bone marrow regeneration after chemotherapy (Lucas et al., 2013). Signals
from the sympathetic nervous system coordinate the circadian egress of HSCs into circulation by
regulating local production of CXCL12 in the synapsed perivascular cells (Giles et al., 2016;
Méndez-Ferrer et al., 2008). Genetic or pharmacological ablation of adrenergic signaling inhibits
G-CSF-induced HSC mobilization (Méndez-Ferrer et al., 2008). Pharmacological or genetic
ablation of adrenergic neurotransmission inhibits G-CSF-induced HSC mobilization (Katayama
et al., 2006). Lastly, non-myelinating Schwann cells are autonomic nerve-ensheathing glial cells.
They are a producer of TGFβ, which is a quiescence signal for HSC (Yamazaki et al., 2011).

Megakaryocytes
Megakaryocytes are terminally-differentiated hematopoietic cells that play an inhibitory
role in HSC expansion via the secretion of CXCL4 and TGFβ (Bruns et al., 2014; Zhao et al.,
2014). Studies showed that depletion of megakaryocytes resulted in specific loss of HSC
quiescence and led to a marked expansion of functional HSCs. In contrast, conditional deletion
of Cxcl4 or Tgf𝛽1 in megakaryocytes increased HSC activation and proliferation (Bruns et al.,
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2014; Zhao et al., 2014). While in response to stress, fibroblast growth factor 1 signaling from
megakaryocytes transiently dominates over TGFβ inhibitory signaling to stimulate HSC
expansion to facilitate the recovery of the hematopoietic system (Zhao et al., 2014).

Monocytes and macrophages
Higher levels of G-CSF are expressed in monocytes and macrophages as part of the
response to sepsis and other inflammatory conditions (Burberry et al., 2014). Depletion of bone
marrow macrophages reduces CXCL12 expression in the bone marrow and promotes HSC
mobilization and extramedullary hematopoiesis (Chow et al., 2011). Monocytes and
macrophages with high expression of α-smooth muscle actin and cyclooxygenase-2 maintain
HSCs and protect them from exhaustion during stress situations by producing prostaglandin E2.
Moreover, macrophages maintain the quiescence of HSCs through the DARC/CD82 ligand
interaction and downstream TGFβ signaling (Hur et al., 2016).

Sinusoidal and arteriolar niches
Functionally distinct perivascular niches are created by sinusoids and arterioles (Acar et
al., 2015; Asada et al., 2017; Chen et al., 2016; Itkin et al., 2016; Kunisaki et al., 2013). There is
a higher ratio of quiescent to cycling HSCs associated with arterioles (Asada et al., 2017;
Kunisaki et al., 2013). However, However, the majority of quiescent and cycling HSCs are
localized to the sinusoids (Acar et al., 2015; Asada et al., 2017; Itkin et al., 2016; Kunisaki et al.,
2013). The sinusoidal and arteriolar microenvironments differ with respect to vessel wall
permeability, oxygen tension and niche factors produced by the residing hematopoietic cells
(Asada et al., 2017; Crane et al., 2017; Itkin et al., 2016; Kunisaki et al., 2013; Spencer et al.,
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2014). First, sinusoids are very leaky as they have a fenestrated basal lamina. They promote HSC
activation and are the exclusive site allowing for cell migration to and from the bone marrow. In
contrast, less permeable arterial blood vessels maintain HSCs in a low oxidative state, keeping
them in a quiescent state (Itkin et al., 2016). HSCs are also more resilient after irradiation thus
they may become more dependent on periarteriolar niches during the regeneration of
hematopoiesis (Ito and Suda, 2014). Second, direct measurement of local oxygen concentration
in the bone marrow showed that the lowest oxygen tension can be found in deeper perisinusoidal
regions. The endosteal region, by contrast, is less hypoxic as it is perfused with small arteries
(Spencer et al., 2014). Thirdly, cytokines produced in distinct vascular niches contribute to HSC
maintenance differently. Selective Cxcl12 deletion from arteriolar NG2-expressing cells caused
HSC reductions and altered HSC localization in bone marrow. In comparison, deletion of Scf in
sinusoidal leptin receptor-expressing cells led to reductions in bone marrow HSC numbers
(Asada et al., 2017).

Differentiation hierarchy and metabolic features of HSCs
HSCs rely heavily on anaerobic glycolysis and have relatively inactive mitochondria
irrespective of oxygen tension, in a manner similar with the Warburg effect in cancer cells (Ito
and Suda, 2014). The activity of specific metabolic pathways and the differentiation state of stem
cells are clearly related (Figure 1.2). Cell differentiation is accompanied by a shift from
anaerobic glycolysis to mitochondrial respiration; oxygen tension increases from the endosteum
to the sinusoids (Gaspar et al., 2014; Wang and Zhong, 2018). The level of oxygen in the various
locations within the bone marrow niche are directly responsible for CXCR4 function and
expression, with higher CXCR4 function and expression in relatively hypoxic environments
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(Wang and Zhong, 2018). Moreover, stem cell fate is dependent on the degree of activation of
mitochondrial metabolism, in addition to other factors (Bigarella et al., 2014). Initially, human
embryonic stem cells rely entirely on glycolysis for their source of energy regardless of oxygen
availability (Panopoulos et al., 2012). After birth, adult stem cells such as HSCs and their
progenitor cells reveal a preference for aerobic glycolysis and a repression of oxidative
phosphorylation (Yeo et al., 2013). Later, terminally differentiated hematopoietic cells lose their
colony-forming capacity and shift from glycolysis to mitochondrial oxidative phosphorylation to
produce ATP. In addition, reprogramming somatic cells to a primitive stage results in a
metabolic switch from oxidative to glycolytic phenotype (Prigione et al., 2014). These results
indicate that the differentiation hierarchy is in close relationship with metabolism, and loss of
primitive stem cell potential is accompanied by a remodeling of the mitochondrial compartment.
Differentiation of HSCs is accompanied by a biogenic shift from glycolysis to mitochondrial
oxidative phosphorylation (Zhang and Sadek, 2014) (Figure 1.2).
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Figure 1.2. Differentiation hierarchy and metabolic features of HSCs. Stem cell fate may be directly
modified by metabolism. The differentiation of stem cells is accompanied by a biogenic shift from
glycolysis to mitochondrial oxidative phosphorylation. HSCs prefer to use glycolysis rather than
mitochondrial oxidative phosphorylation as a main energy source. Following differentiation, terminally
differentiated cells lose colony-forming capacity and shift from glycolysis to mitochondrial oxidative
phosphorylation. Abbreviations: ESC, embryonic stem cells; iPSC, induced pluripotent stem cells; HSCs,
hematopoietic stem cells; HPCs, hematopoietic progenitor cells.
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Interestingly, recent studies have demonstrated unique mitochondrial bioenergetic
features associated with leukemia and drug resistance (Farge et al., 2017; Kao et al., 2019).
Namely, increased oxidative phosphorylation was observed in acute myeloid leukemia (AML)
under chemotherapeutic selective pressure but was not exclusive to the leukemia stem cell
compartment (Farge et al., 2017). This increase in oxidative phosphorylation accompanies
increased mitochondrial biogenesis and so has been postulated to be due to an increased reliance
on this metabolic pathway (Farge et al., 2017). It has therefore been postulated that targeting
mitochondrial metabolism may represent a strategy to overcome this new hallmark of AML drug
resistance (Farge et al., 2017). However, another study has suggested that increased reliance on
oxidative phosphorylation may be representative of mitochondrial inefficiency due to other
energetic and metabolic changes (Kao et al., 2019). Intriguingly, alterations in mitochondrial
bioenergetics were observed to be associated with and possibly secondary to alterations in
sphingolipid metabolism (Kao et al., 2019). Not surprisingly, dysfunctional sphingolipid
metabolism has also been associated with AML and therapy resistance (Barth et al., 2019; Kao et
al., 2019). Overall, this highlights the importance of metabolic changes that occur during
hematologic malignancy and demonstrates the relevance of metabolic-targeting therapeutic
strategies.

Malignant transformation of HSCs
Hematologic malignancies such as leukemia do not propagate efficiently in vivo outside
of the bone marrow and are difficult to grow ex vivo. This suggests that supporting cells within
the bone marrow niche may help to support or drive the malignant transformation of HSCs.
Furthermore, malignant HSCs may remodel the niche to increase its own support, while
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suppressing normal hematopoiesis (Calvi and Link, 2015; Krause and Scadden, 2015; Zhang and
Sadek, 2014). Alteration of the marrow niche is an important and necessary step in
leukemogenesis, which is a hypothesis supported by the observation that fewer than one in one
million AML cells possess stem cell-like activity (Behrmann et al., 2018).

Notch signaling
Notch signaling in endothelial cells leads to the expansion of HSC niches by inhibiting
Cxcl12 expression in bone, which increases capillary perivascular cells and arteriole formation
and elevates cellular SCF levels (Kusumbe et al., 2016). Defects in this signaling pathway have
been observed to lead to the development of myeloproliferative disease and have for many
decades been linked to the development of T-cell neoplasms (Lampreia et al., 2017; Weber and
Calvi, 2010). Further, it appears that constitutive Notch activation via transduction of HSCs with
active Notch1 intracellular domain increases self-renewal of HSCs (Weber and Calvi, 2010).
Constitutive Notch activation prevents HSC differentiation into hematopoietic progenitors
(Weber and Calvi, 2010). To disrupt the cancer-stromal interactions in leukemia, CXCR4
antagonists have been clinically used to promote mobilization of leukemic cells from the
protective microenvironment, making them more sensitive to conventional chemotherapy (Liu et
al., 2016; Tsou et al., 2018).
Alterations in bone marrow stromal cells have been shown to be sufficient to initiate
myeloproliferative disorders (Calvi and Link, 2015). In acute lymphoblastic leukemia and
chronic myeloid leukemia, malignant cells were shown to have increased G-CSF production and
reduced homing and retention in the bone marrow, which was related to decreased Cxcl12
expression in bone marrow stromal cells (van den Berk et al., 2014; Zhang et al., 2012).
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Osteogenic differentiation has also been shown to be reduced in myelodysplastic syndrome
(MDS)-derived MSC (Geyh et al., 2013). In fact, MSCs from a wide diversity of MDS subtypes
are structurally, epigenetically, and functionally altered, which leads to impaired stromal support
and may contribute to deficient hematopoiesis in MDS (Geyh et al., 2013).
An activating mutation of β-catenin in mouse osteoblasts has also been shown to alter the
differentiation potential of myeloid and lymphoid progenitors, leading to development of AML.
This demonstrates a link between genetic alterations in osteoblasts and the development of AML
(Kode et al., 2014). Moreover, this shows that an altered microenvironment can serve as the
inciting event in hematologic malignancy.
In addition, leukemic bone marrow infiltration in an MLL-AF9 AML model has been
shown to be promoted by neuropathy of the sympathetic nervous system (Hanoun et al., 2014).
Development of AML damages the sympathetic nervous system and disrupts the quiescence of
perivascular MSCs. This can lead to increased osteoblastic differentiation at the expense of HSCmaintaining periarteriolar niche cells. Moreover, stromal β2-adrenergic receptors have been
shown to regulate leukemia stem cells. This is evidenced by rescue of the healthy HSC niche by
β2 agonist treatment, which otherwise limits leukemia stem cell expansion (Hanoun et al., 2014).

Malignant HSCs remodel the bone marrow niche
Just as the bone marrow niche may have profound effects on HSC behavior, malignant
HSCs may also shape the microenvironment to selectively enhance their own support over
normal HSCs (Calvi and Link, 2015). In chronic myeloid leukemia (CML), malignant cells
release exosomes that stimulate bone marrow stromal cells to produce IL-8 to promote CML cell
survival (Corrado et al., 2014). The secretion of IL-8 is part of the crosstalk between CML cells
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and bone marrow stromal cells mediated by exosomes (Corrado et al., 2014). Furthermore, in
myeloproliferative neoplasms, leukemic cells stimulate MSCs to overproduce functionally
altered osteoblastic lineage cells, which accumulate in the bone marrow cavity as inflammatory
myelofibrotic cells (Schepers et al., 2013). Malignant HSCs have also been found to produce IL1β to trigger neural damage and Schwann cell death, which further causes MSC reduction
(Arranz et al., 2014). Finally, healthy MSCs have been shown to adopt MDS-MSC-like
molecular features when exposed to MDS cells, indicative of an instructive remodeling of the
microenvironment (Ito and Suda, 2014).

Conclusions
This review has illustrated the contributions of multiple cell populations within the bone
marrow microenvironment to the complex regulation of HSC function. There is a continuing and
further need to understand how the niche controls HSC function during stress situations,
including during infection, malignancy, and during therapy. Examining the crosstalk between
HSCs and their niche may provide targetable pathways to alter the HSC niche in such a way that
it becomes less hospitable to malignant cells (Krause and Scadden, 2015). In this manner,
targeting the HSC niche itself is an attractive avenue for the treatment of hematologic
malignancies. Future work utilizing high resolution single-cell methods, as well as endogenous
labeling and tracking of stem cells, may further foster studies on the complex interplay occurring
within the microenvironment of the bone marrow.
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1.2. Brief Overview of Hematologic Disorders

Abstract
Hematologic disorders are diseases related to blood. They may affect the production of
blood and its components, such as blood cells, hemoglobin, blood proteins, bone marrow,
platelets, blood vessels, and the spleen. Common blood disorders include anemia, hemophilia,
myelodysplastic syndrome, blood cancers such as leukemia (including acute myeloid leukemia,
chronic myeloid leukemia, acute lymphocytic leukemia, and chronic lymphocytic leukemia),
multiple myeloma, and lymphoma (Hodgkin lymphoma and non-Hodgkin lymphoma).

Anemia
Anemia occurs when there are not enough red blood cells in the body or when red blood
cells do not function properly (Table 1.1). It is diagnosed when the hemoglobin value is less than
13.5 gm/dl in a man or less than 12.0 gm/dl in a woman by a blood test (Conrad, 1990).
Depending on the size of the red blood cells, anemia can be classified as microcytic anemia,
macrocytic anemia, normocytic anemia. Based on the amount of hemoglobin in each cell, anemia
can be classified by severity as mild, moderate, or severe (Powell and Achebe, 2016).
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Table 1.1. Brief description for major hematologic disorders

Anemia

Hemophilia
Myelodysplastic
syndrome
Acute myeloid
leukemia
Chronic myeloid
leukemia
Acute
lymphocytic
leukemia
Chronic
lymphocytic
leukemia
Multiple
myeloma
Hodgkin
lymphoma
Non-Hodgkin
lymphoma

Brief disease description
Absolute decrease in red blood
cell mass
An inherited genetic defect that
impairs the body's ability to clot
properly
A group of cancers in which
immature blood cells in the bone
marrow do not become healthy
blood cells
A type of cancer that originates
from immature myeloid cells
A form of leukemia
characterized by the proliferation
of mature granulocytes
A type of cancer that originates
from the immature lymphoid line
of blood cells
A form of leukemia
characterized by the proliferation
of mature lymphocytes
A cancer of plasma cells

Treatment options
Changing diet, taking dietary
supplements, treating the underlying
disease, immunosuppressive
medications, blood transfusions
Commercially prepared clotting factors
Blood products, hematopoietic growth
factors, chemotherapy,
hypomethylating agents, allogeneic
stem cell transplantation
Chemotherapy, hematopoietic stem cell
transplant, CARTs
Tyrosine-kinase inhibitors, allogeneic
bone marrow or stem cell
transplantation
Chemotherapy, tyrosine-kinase
inhibitors, immunotherapy, radiation
therapy, one marrow transplant
Chemotherapy, targeted therapy,
biological therapy
Chemotherapy, autologous
hematopoietic stem cell transplant
Chemotherapy, radiation therapy,
immunotherapy, stem cell transplant

A type
of lymphoma that originates
from a specific type of
lymphocytes (Hodgkin cells)
A diverse group of blood cancers Radiation therapy, chemotherapy,
that includes all types of
immunotherapy, targeted therapy, stem
lymphomas except Hodgkin
cell transplant
lymphomas
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Causes
Causes of anemia include decreased production of red blood cells, increased destruction
of red blood cells, blood loss, and body fluid overload. Conditions that decrease the production
of red blood cells include poor diet, intestinal disorders, and kidney failure. Conditions that
increase the destruction of red blood cells include thalassemia, chronic disease, cancer, and
infections. Blood loss may arise by trauma, surgery, or menstruation. Pregnancy or hypervolemia
caused by excessive sodium or fluid intake can lead to fluid overload (Powell and Achebe,
2016).

Pathophysiology
Anemias arising from different conditions have different pathophysiological processes.
For anemia caused by poor diet lacking iron, decreased availability of iron leads to progressive
depletion of bone marrow iron stores and eventually impairs erythropoiesis. For anemia caused
by poor diet lacking vitamin B12 or folate, defective DNA synthesis leads to delayed nuclear
maturity compared to the cytoplasm. This dyspoiesis results in intramedullary cell death and
ineffective erythropoiesis (Cuskelly et al., 1996). For anemia caused by thalassemia, decreased
production of one or more globin polypeptide chains leads to an abnormal form of hemoglobin
being synthesized and, consequently, large numbers of red blood cells being destroyed
(Marengo-Rowe, 2007).

Signs and symptoms
Since red blood cells carry hemoglobin, an iron-rich protein that transports oxygen
throughout the body, patients with anemia may experience symptoms such as weakness,
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shortness of breath, dizziness, irregular heartbeat, headache, cold hands or feet, and pale skin.
Anemia often starts slowly without any symptoms. As the disease progresses, more symptoms
may appear (Lewis, 1976).

Treatment
Treatment for anemia depends on cause and severity. For anemia caused by malnutrition,
treatment varies from changing diet to taking dietary supplements. For anemia caused by chronic
disease, cancer, or infections, treating the underlying disease is the solution. For aplastic anemia,
which is caused by bone marrow failure, immunosuppressive medications and blood transfusions
may be used for treatment (Stauder et al., 2018).

Hemophilia
Hemophilia is a genetic disorder that impairs the body's ability to clot properly (Table
1.1). This results in external bleeding after an injury or surgery, or internal bleeding inside the
brain or joints. There are two main types of hemophilia: hemophilia A, which occurs due to low
levels of clotting factor VIII; and hemophilia B, which occurs due to low levels of clotting factor
IX (CDC, 2020). Both genes are on the X chromosome. Since females have two X chromosomes
and males have one, males are more likely to have hemophilia. A female with one affected X
chromosome is a carrier of hemophilia and may pass it on to her son.

Causes
Hemophilia is mainly caused by X-linked recessive genetic mutations. Hemophilia A is
caused by a genetic mutation on clotting factor VIII. Hemophilia B is caused by a genetic
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mutation on clotting factor IX. As with all genetic disorders, it is also possible to acquire the
disease through spontaneous mutation (Peyvandi et al., 2016).

Pathophysiology
When an injury disrupts the endothelial lining of a blood vessel, coagulation begins.
Exposure of blood to the subendothelial space initiates two processes: changes in platelets to
form a plug; and the exposure of subendothelial tissue factor to clotting factors, which eventually
leads to fibrin formation to strengthen the platelet plug. When clotting factors cannot work
properly or are missing, people cannot form fibrin stands to strengthen the platelet plug. Thus,
patients with hemophilia tend to have longer bleeding time or even bleed spontaneously (Furie
and Furie, 2005).

Signs and symptoms
Symptoms caused by hemophilia vary with severity. Bleeding is the most common
symptom, which can happen in the skin (bruise), mouth, muscle, soft tissue (hematoma), brain,
and joints. The bleeding can damage organs and tissues, and it can even be life-threatening
(CDC, 2020).

Treatment
There is no cure for hemophilia yet. The goal of current treatment is to prevent bleeding
episodes. The mild and moderate severity patients rarely need treatment. When the disease
becomes severe, commercially prepared clotting factors should be used to decrease the damage
to the body. The factors can either be isolated from human blood serum, recombinant, or a
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combination of the two. 20% of patients with hemophilia may gradually develop antibodies to
the clotting factors, which makes the treatment more difficult (Peyvandi et al., 2016). However,
in recent years patients can be diagnosed since infants during circumcision, there is a shift from
treatment to prevention (Commissioner, 2020).

Myelodysplastic syndrome
Myelodysplastic syndrome (MDS) is a group of clonal bone marrow neoplasms that arise
from the expansion of abnormal hematopoietic stem cells (Table 1.1). It is characterized by
morphologic dysplasia in hematopoietic cells and peripheral cytopenia (Arber et al., 2016).
Patients with MDS have an increased risk of AML transformation. It is most commonly
diagnosed in people in their 70s in the US. The risk increases as a person gets older (GarciaManero et al., 2020).

Risk factors
There are several known risk factors for MDS. Older age is one of the most important
risk factors for MDS. Men are more common to get MDS than women. Prior treatment with
chemotherapy, certain inherited syndromes, some environmental exposures and smoking
increase the risk of MDS (Poynter et al., 2017).

Pathophysiology
The pathophysiology of MDS is characterized by a multi-step process involving
cytogenetic changes and/or gene mutations, abnormalities of the bone marrow microenvironment
and widespread gene hypermethylation at advanced stages (Fenaux et al., 2020). A set of
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recurrently mutated genes are central to the pathogenesis of MDS. These genes are organized
into a limited number of cellular processes, including RNA splicing, epigenetic and traditional
transcriptional regulation, and signal transduction (Fenaux et al., 2020).

Signs and symptoms
Signs and symptoms are generally related to the decrease of blood cells. Low red blood
cell counts are related to chronic tiredness, shortness of breath, chilled sensation, and sometimes
chest pain. Low counts of white blood cells, which fight diseases, can increase susceptibility to
infection. Low numbers of platelets, which function in clotting, may lead to increased
susceptibility to bleeding and bruising, as well as subcutaneous hemorrhaging (Hasserjian,
2019).

Treatment
The goals of current therapies are to control symptoms and improve overall survival. The
initial step is assessing a patient’s eligibility for allogeneic hematopoietic stem cell
transplantation, which is the only potentially curative approach but is associated with substantial
morbidity and graft-versus-host disease (Cazzola, 2020). For patients who are not eligible for
transplantation, risk stratification can help inform clinical decision making. For patients with
lower-risk MDS, the choice of a medical treatment is largely based on the specific disease
subtype. Administration of erythropoiesis-stimulating agents can increase red-cell production
and ameliorate anemia. Patients with higher-risk MDS have a median life expectancy of less than
two years. For such patients, treatment is aimed at ameliorating cytopenia as well as at
preventing evolution to AML and thus prolonging survival (Malcovati et al., 2013).
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Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is a type of blood malignancy that originates from
differentiation arrest of immature myeloid progenitor cells (Table 1.1). These cells grow rapidly
and interfere with normal blood cell production in the bone marrow. AML is the most common
form of acute leukemia in adults. The disease is fatal within weeks or months if left untreated,
with a median of 4.3 months (Estey, 2021). The median age at diagnosis is 68 years in the US
(Shallis et al., 2019).

Risk Factors
A number of risk factors for developing AML have been identified. “Preleukemic” blood
disorders such as MDS and myeloproliferative neoplasms, hereditary defects such as Down
Syndrome, exposure to chemicals such as benzene, and exposure to ionizing radiation have been
identified to increase the risk of developing AML (Belson et al., 2007).

Pathophysiology
AML can arise in patients with an underlying hematological disorder or as a consequence
of prior therapy, but in majority of cases, it appears as a de novo malignancy (Sill et al., 2011).
The pathogenesis of AML involves the abnormal proliferation and differentiation of a clonal
population of myeloid stem cells, which depends heavily on the interactions between different
somatic alterations and chromosomal rearrangements (De Kouchkovsky and Abdul-Hay, 2016).
Actually, chromosomal rearrangements and genetic mutations are identified in more than 97% of
cases (Patel et al., 2012). For example, chromosomal translocation t(8:21) in core-binding factor
AML results in the formation of chimeric proteins, which alter the normal maturation process of
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myeloid precursor cells. This will eventually result in the accumulation of poorly differentiated
myeloid cells and entity of AML (De Kouchkovsky and Abdul-Hay, 2016).

Signs and symptoms
Most of the clinical manifestations of AML reflect the lack of normal mature blood cell
production as leukemic cells accumulate and replace normal cells. The early signs of AML are
often vague and nonspecific. The majority of patients presents with a combination of
leukocytosis and signs of bone marrow failure such as shortness of breath, easy bruising and
bleeding, and susceptibility to infections. Fatigue, anorexia and weight loss are common
complaints (De Kouchkovsky and Abdul-Hay, 2016).

Treatment
AML requires different therapeutic interventions since it is a heterogeneous group of
disorders. There is a shift from “one size fits all” approach towards more personalized treatment
based on the patients’ genomic signature (Nair et al., 2020). Nonchemotherapy regimens
consisting of all trans-retinoic acid and arsenic trioxide in acute promyelocytic leukemia resulted
in cure rates exceeding 80% (Lo-Coco et al., 2013). Using known drugs in improved regimens
(fludarabine, high-dose cytarabine, anthracyclines, gemtuzumab, ozogamicin) increased the cure
rate in core binding factor AML to 80% (Kantarjian, 2016). Newly approved drugs provide fresh
hope for other types of AML patients, presenting a steppingstone into a new era of precision
treatment (Tiong and Wei, 2019). These include a new liposomal formulation of cytarabine and
daunorubicin, and a B-cell lymphoma 2 inhibitor in combination with hypomethylating agents,
among others (Nair et al., 2020).
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Chronic myeloid leukemia
Chronic myeloid leukemia (CML) is a form of leukemia characterized by the
proliferation of immature and maturing granulocytes in the bone marrow (Table 1.1). In Western
countries, CML accounts for 15% of all leukemias affecting adults. The average age at diagnosis
is around 64 years (Turkina et al., 2020).

Risk factors
The exact cause of CML is still unknown, but exposure to ionizing radiation from events
such as atomic bombing has been implicated (Corso et al., 1995). Other agents such as benzene
are also possible causes (Vlaanderen et al., 2012).

Pathophysiology
CML is known to be caused by a single, specific genetic mutation that results from a
chromosomal translocation called the Philadelphia chromosome. The cytogenetic aberration
consists of a reciprocal translocation between the long arms of chromosomes 22 and 9 [t (9; 22)],
which results in a BCR/ABL fusion gene encoding a chimeric protein with strong tyrosine kinase
activity. The continuous expression of this protein leads to the development of the CML
phenotype (Quintás-Cardama and Cortes, 2009).

Signs and symptoms
CML progresses through three phases: chronic, accelerated, and blast. In the chronic
phase, mature granulocytes proliferate. Most patients are diagnosed in this phase, which is most
often asymptomatic. If left untreated, patients progress to the accelerated phase after 3-5 years, in
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which additional cytogenetic abnormalities occur. Symptoms during this phase include bleeding,
petechiae, and ecchymosis. Blast is the terminal phase of CML in which cells with additional
mutations proliferate and the disease progresses rapidly. Symptoms in this stage include fever,
bone pain, and a rapidly enlarging spleen (Bonifacio et al., 2019). Young patients with CML
may already have a more aggressive form of CML by the time they are diagnosed (Tefferi,
2006).

Treatment
The goals of treatment are to achieve hematologic, cytogenic, and molecular remission.
The first line of treatment is tyrosine-kinase inhibitors such as imatinib and dasatinib, which
specifically target BCR-ABL, the fusion protein caused by the Philadelphia chromosome. With
the current use of these inhibitors, there is no statistically significant difference between the
survival rates of CML patients and the general population (Gambacorti-Passerini et al., 2011).
Allogeneic bone marrow or stem cell transplantation is a therapeutic option particularly for
advanced phase CML.

Acute lymphocytic leukemia
Acute lymphocytic leukemia (ALL) is a cancer of the lymphoid line of blood cells
characterized by large numbers of immature lymphocytes (Table 1.1). It is the most common
pediatric malignancy. In the past ALL progressed rapidly and untreatable, but now the survival
probability is as high as 80-90% in children and 30-40% in adults (Kato and Manabe, 2018; Paul
et al., 2016).
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Risk factors
Although most ALL arises in healthy individuals, inherited genetic susceptibility and
environmental risk factors have been identified in some patients (Malard and Mohty, 2020).
People carrying inherited genetic abnormalities such as Down syndrome, Li-Fraumeni syndrome,
or neurofibromatosis type 1 have increased risk of developing ALL, although ALL is not
hereditary. Common infections such as influenza during pregnancy may also indirectly lead to
ALL by triggering abnormal immune responses (Cazzaniga et al., 2017).

Pathophysiology
The genetic changes that lead to ALL include chromosomal translocations such as the
translocation of C-MYC, intrachromosomal rearrangements such as the generation of ETV6RUNX1 fusion gene, changes in the number of chromosomes in leukemic cells such as trisomy 4,
and additional mutations in individual genes (Hunger and Mullighan, 2015).

Signs and symptoms
The clinical presentation of ALL is nonspecific. Symptoms may include weight loss,
fever, night sweats, loss of appetite, and enlarged liver or spleen. The T-cell subtype of ALL
often causes an enlarged thymus, which can press on the trachea or the superior vena cava,
causing coughing or headaches (Malard and Mohty, 2020).

Treatment
Current treatment options include chemotherapy, tyrosine-kinase inhibitors,
immunotherapy, radiation therapy, and bone marrow transplant. Chemotherapy is the main
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treatment for patients with ALL and consists of three phases: remission induction, consolidation,
and maintenance. Tyrosine-kinase inhibitors such as imatinib are often incorporated into the
treatment plan for people with the Philadelphia chromosome. Immunotherapies used for ALL
include chimeric antigen receptors (CARs) T cells. They are genetically modified and patientderived in order to bind to leukemia cells that express specific antibodies (Mardiana and Gill,
2020). In 2017, the U.S. FDA approved the CAR-T cell therapy Novartis’ Kymriah for treatment
of ALL. The therapeutic CAR-T cells are created from a patient’s own cells and reprogrammed
to detect CD19, which target and destroy the B cells (Liu et al., 2017). Bone marrow transplant is
often suggested for relapsed patients (Nagler et al., 2020).

Chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is caused by the monoclonal expansion and
progressive accumulation of mature-appearing neoplastic B lymphocytes (Table 1.1). These have
a distinct immune phenotype characterized by expression of B cell markers such as CD19 and
CD20, which are not usually expressed on non-malignant B cells (Hallek et al., 2018a). CLL is
the most common leukemia overall with a median age at diagnosis of 71 (Woyach, 2018). Many
patients experience an indolent disease course and never require therapy, but some patients,
especially the very elderly and those with medical comorbidities, will die from their disease
(Strati et al., 2017).

Risk factors
A limited number of risk factors for CLL have been identified. Having a relative with
CLL has been found to contribute to disease risk, indicating that inherited predisposition is a risk
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factor (Cerhan and Slager, 2015). Reduced sun exposure, allergic immune dysfunction, exposure
to herbicides and pesticides, and hepatitis C virus infection can also be associated with an
increased risk (Slager et al., 2014).

Pathophysiology
Genetic alterations including chromosomal alterations, somatic mutations, and alterations
in miRNA have been found to be associated with the development of CLL by promoting the
proliferation of B lymphocytes (Calin et al., 2005). These CLL cells follow chemokine gradients
into lymph nodes and form proliferation centers in which they are exposed to chemokines,
integrins, and cytokines from surrounding cells (Hallek et al., 2018a). CLL cells usually display
an unusual but characteristic pattern of molecules, including surface antigen CD5, B-cell
antigens CD19, CD20, and CD23. In addition, all the CLL cells within one individual are clonal
and genetically identical (Hallek et al., 2018b).

Signs and symptoms
Patients with CLL usually don't have any symptoms for at least a few years since the
lymphocytes grow and spread very slow. The most common presentation of CLL is the
incidental discovery of lymphocytosis on a complete blood count. Then as the B cells infiltrate
the bone marrow, patients develop more symptoms such as lymphadenopathy, B symptoms
(fever, night sweats, weight loss, fatigue) or cytopenia (anemia, thrombocytopenia, neutropenia)
(Hallek et al., 2018b).
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Treatment
Since CLL progresses slowly in most cases, it is not treated until the onset of symptoms.
Current treatment for CLL has changed dramatically over the last 10 years with first the addition
of monoclonal antibodies to chemotherapy, and subsequently the introduction of targeted
therapies for this disease (Woyach, 2018). Current targets drugs used for CLL include Bcl-2
inhibitor venetoclax, CD20 antibody rituximab, and CD52 antibody alemtuzumab. Risk-based
individualized therapy is now possible, ranging from chemoimmunotherapy for low-risk CLL to
novel molecularly targeted therapy primarily with BTK inhibitors such as ibrutinib for high-risk
disease (Burger and O’Brien, 2018). For patients who are too frail to be considered candidates
for the novel agents, allogenic stem cell transplant has been considered the treatment choice of
these patients and the only approach offered with curative intent in the disease (Gribben, 2018).

Multiple myeloma
Multiple myeloma (MM) is a neoplastic plasma-cells disorder, which is characterized by
clonal proliferation of malignant plasma cells in the bone marrow, secreted monoclonal protein
in the blood or urine, and associated organ dysfunction (Palumbo, 2011) (Table 1.1). It is
preceded by monoclonal gammopathy of uncertain significance that progresses to smoldering
myeloma and, finally, to symptomatic myeloma (Kuehl and Bergsagel, 2002). MM accounts for
13% of hematological cancers. The median age at diagnosis 69 years and the five-year survival
rate is 53.9% in the US (Padala et al., 2021).
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Risk factors
A few risk factors could affect someone’s chance of getting MM. Someone who has a
sibling or a parent with MM and has African ancestry is more likely to get MM than someone
who does not. Actually, several susceptibility regions have been identified in MM (Koura and
Langston, 2013). Being overweight or obese also increases a person’s risk of developing
myeloma (Roberts et al., 2010).

Pathophysiology
MM is characterized by the proliferation of plasma cells, which are differentiated from B
cells. B cells are a type of white blood cell of the lymphocyte subtype. They originate from the
bone marrow and migrate into the spleen to complete development. They are then activated in
the secondary lymphoid organs such as the spleen and lymph nodes by receiving a constant
supply of T cell-dependent antigens through circulating lymph. Most of these B cells become
plasma cells and begin producing and secreting large volumes of antibodies. In MM, genetic or
epigenetic mutations happen in a plasma cell, which establishes an abnormal clone of bone
marrow plasma cells. If left uncontrolled, the disease progresses from monoclonal gammopathy
of undetermined significance to smoldering multiple myeloma, multiple myeloma, and
eventually to plasma cell leukemia (Dutta et al., 2017).

Signs and symptoms
Presenting symptoms of MM are vague and nonspecific. The most common clinical
manifestations of MM are anemia, infections, bone disease, and renal failure. Back pain, weight
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loss, or abnormal lab results are indications for the presence of MM, especially in older patients
(Goldschmidt et al., 2016).

Treatment
Different types of treatment may be combined at the same time or used after one another
depending on the stage of the cancer. If the disease is in an early stage like smoldering multiple
myeloma, no immediate treatment is needed as patients can do well for years. When patients
develop end-organ damage, it is the indication for treatment (Röllig et al., 2015). Patients are
often given a combination of 2 or 3 drugs containing bortezomib, lenalidomide, or
dexamethasone. The drugs chosen depend on the patient’s health including their kidney function,
and whether a stem cell transplant is planned. Some patients are given additional cycles of
treatment after transplant. This is called consolidation treatment and increases the chance of a
complete response (Mohty et al., 2015). Supportive treatments such as blood transfusions may
also be used as part of the treatment plan.

Hodgkin lymphoma
Lymphoma is cancer that begins in cells of the lymph system. Hodgkin lymphoma (HL)
originates from a specific type of lymphocyte and accounts for about 10% of all lymphomas
(Table 1.1). In 1832, Thomas Hodgkin described a case series of enlarged lymph nodes, later to
be known as HL (Cirillo et al., 2019). There are two main types of HL: classical HL (cHL),
which accounts for 90% of all cases; and nodular lymphocyte predominant HL (NLPHL), which
accounts for less than 10%. HL is most common in two different age groups: young adults
between 15 to 35 years old and older adults over age 50 (Thyss et al., 2014).
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Risk factors
The etiology of HL is not well understood. People who have been infected with Epstein–
Barr virus or human immunodeficiency virus are at greater risk (Shanbhag and Ambinder, 2018).
The incidence of HL also increases after solid organ transplantation and in patients with a history
of autoimmune conditions, such as rheumatoid arthritis, systemic lupus erythematosus, and
sarcoidosis (Landgren et al., 2006).

Pathophysiology
In around 1900, Dorothy Reed and Carl Sternberg characterized the abnormal
mononucleated Hodgkin and multinucleated Reed-Sternberg cells that are pathognomonic for the
disease (Küppers, 2009). HL results from the clonal transformation of B cells, giving rise to
pathognomonic Reed-Sternberg cells in cHL or popcorn cells in NLPHL. Reed–Sternberg cells
are usually CD30 and CD15 positive, but negative for CD20 and CD45 (Cirillo et al., 2019). The
popcorn cells in NLPHL are variants of Reed-Sternberg cells and have a popcorn-like
appearance. Unlike classic Reed-Sternberg cells, these cells are CD15 and CD30 negative while
positive for the B cell marker CD20 (Saini et al., 2011).

Signs and symptoms
The most common symptom of HL is the painless enlargement of cervical or axillary
lymph nodes (Ansell, 2015). As the disease spreads through internal lymph nodes, liver, or bone
marrow, systematic symptoms (B symptoms) such as fever, night sweats, and weight loss
develop. Other possible symptoms include itching skin, fatigue, and loss of appetite (Shanbhag
and Ambinder, 2018).
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Treatment
HL is considered a prime example of treatment success with more than 80% cure rates
using modern combined modality therapies (Mottok and Steidl, 2018). The exact choice of
treatment depends on the precise stage of the disease. Patients in early stages are effectively
treated with combination chemotherapy followed by involved-field radiation therapy. Patients in
advanced-stage disease are often offered chemotherapy together with radiation therapy either for
a longer duration or of a different type. For patients who are not cured with the first-line therapy,
multiple second-line therapies such as immunotherapy or stem cell transplant are considered
acceptable (Ansell, 2015).

Non-Hodgkin lymphoma
Non-Hodgkin lymphoma (NHL) is a diverse group of blood cancers that includes all
types of lymphomas except HL (Table 1.1). It represents a wide spectrum of illnesses that vary
from the most indolent to the most aggressive types. They arise from lymphocytes that are at
various stages of development, and the characteristics of the specific disease subtype reflect
those of the cell from which they originate (Armitage et al., 2017). NHL is the most common
hematologic malignancy and the fifth most common type of cancer in more developed regions of
the world (Morton et al., 2014). It represents a wide spectrum of illnesses that vary from the most
indolent to the most aggressive malignancies (Armitage et al., 2017).

Risk factors
Various factors have been found to affect an individual’s risk of developing NHL. Some
of these factors are common while some of them are subtype specific (Morton et al., 2014).
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Common risk factors include family history of NHL, recreational sun exposure, hay fever,
allergy, and socioeconomic status (Morton et al., 2014). Take immunosuppressant drugs or
having any medical conditions that weakens the immune system, such as autoimmune diseases,
HIV infection, or undergoing organ transplantation is also related to higher risk of getting NHL
(Shiels et al., 2013; Zintzaras et al., 2005). Obesity is a risk factor for diffuse large B-cell
lymphoma (Castillo et al., 2014). The Epstein-Barr virus is closely associated with both Burkitt
lymphoma and nasal NK–T-cell lymphoma (Kwong, 2005; Saha and Robertson, 2011). Hepatitis
C virus has been associated with splenic marginal zone lymphoma and diffuse large B-cell
lymphoma (Giordano et al., 2007).

Pathophysiology
NHL is a cancer with a number of subgroups. It arises from the clonal transformation of
lymphocytes. B cell lymphomas account for more than >85% of cases of NHL, while the others
are derived from T cells or natural killer cells (Chaudhari et al., 2019). The classification of NHL
is complex and ever evolving, reflecting new insights into the cells of origin and the biologic
bases of these heterogeneous diseases. Currently, there are more than 50 different subtypes listed
in the latest World Health Organization classification (Swerdlow et al., 2016). For nonspecialists, NHL is most usefully categorized as low grade (indolent) or high grade (aggressive)
lymphoma. Follicular lymphoma and diffuse large B cell lymphomas are the most common
indolent and aggressive subtypes, respectively (Chaudhari et al., 2019).
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Signs and symptoms
The presenting features of NHL are diverse. Patients may be entirely asymptomatic. The
most common symptom of NHL is the painless enlargement of cervical or axillary nodes (AlNaeeb et al., 2018). Patients may later have systemic symptoms such as fevers, drenching night
sweats, weight loss, pruritis, and fatigue. Since NHL can involve any organ in the body, a myriad
of presentations are possible, mimicking a wide range of other conditions (Armitage et al., 2017).

Treatment
The principles of treatment differ for high-grade and low-grade lymphoma. For patients
with low grade lymphomas and no significant signs or symptoms, a "watch and wait" approach
can be used (Al-Naeeb et al., 2018). High grade NHL may progress rapidly and requires urgent
treatment. Standard treatment includes radiation therapy, chemotherapy, immunotherapy,
targeted therapy, or stem cell transplant. Patients who fail to respond to first line chemotherapy
or who relapse after chemoimmunotherapy may consider clinical trials as they are the only way
to get state-of-the-art cancer treatment (Chiappella et al., 2017).
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1.3. Epigenetics and Sphingolipid Metabolism in Health and Disease2

Abstract
Sphingolipids represent one of the major classes of bioactive lipids. Studies of
sphingolipids have intensified in the past several years, revealing their roles in nearly all cell
biological processes. In addition, epigenetic regulation has gained substantial interest due to its
role in controlling gene expression and activity without changing the genetic code. In this
review, we first introduce a brief background on sphingolipid biology, highlighting its role in
pathophysiology. We then illustrate the concept of epigenetic regulation, focusing on how it
affects the metabolism of sphingolipids. We further discuss the roles of bioactive sphingolipids
as epigenetic regulators themselves. Overall, a better understanding of the relationship between
epigenetics and sphingolipid metabolism may help to improve the development of sphingolipidtargeted therapeutics.

Sphingolipid biology
Sphingolipids are a class of bioactive lipids that contain a sphingoid base backbone, they
are a class of aliphatic amino alcohols that include sphingosine and are found in all cellular and
subcellular membranes (Borodzicz et al., 2015). There are variety of sphingolipids including
ceramides and dihydroceramides, phytoceramides, sphingosine and dihydrosphingosine
(sphinganine), various phosphorylated sphingolipids, sphingomyelins, glycosphingolipids,
gangliosides, cerebrosides, and sulfatides. Sphingolipids can be formed by de novo synthesis or

2
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generated through salvage pathways from existing sphingolipids via various catabolic enzyme
activities (Figure 1.3). Ceramide can be deacetylated to form sphingosine, and subsequently
phosphorylated to form sphingosine-1-phosphate (S1P). Ceramide can also be glycosylated to
form glycosphingolipids or acquire a phosphocholine group to form sphingomyelin. The
synthesis and degradation of sphingolipids are finely tuned to maintain cellular homeostasis. On
the cell surface, they can function as adhesion sites for extracellular proteins and serve both as
structural lipids and signaling molecules (Iqbal et al., 2017). In 1996, the “sphingolipid rheostat”
model was proposed. It postulated that ceramide and S1P differentially regulate cellular
signaling pathways involved in cellular death and proliferation/survival, respectively. Factors
including growth factors, cellular stress and inflammatory mediators may alter the balance
between ceramide and S1P to control cell fate (Evangelisti et al., 2016).
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Figure 1.3. Ceramide is at a hypothetical center of sphingolipid metabolism. De novo ceramide
synthesis initially generates dihydro-sphingoid species prior to desaturation. Salvage ceramide synthesis,
or turnover by the successive activities of acidic/lysosomal-localized catabolic enzymes, generates
sphingosine that escapes the lysosome to be re-acylated to ceramide. Glucosylceramide synthase (GCS);
cerebrosidase (GBA); sphingomyelin synthase (SGMS); ceramide kinase (CERK), ceramide-1-phosphate
phosphatase (C1PP); ceramidases (CDase); ceramide synthases (CERS); sphingosine kinases (SPHK);
S1P phosphatase (S1PP).
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Pathophysiological roles of sphingolipids
Structurally diverse sphingolipids are bioactive and have roles in multiple biological
processes. which include cell growth, cell death, cell differentiation, inflammation, apoptosis and
angiogenesis (Hannun and Obeid, 2018). Consequently, abnormalities in sphingolipid
homeostasis can lead to or contribute to aberrant pathophysiological processes such as metabolic
disorders, cancer, inflammation, neurological syndromes and cardiovascular disease (SchneiderSchaulies and Schneider-Schaulies, 2015).

Metabolic disorders
Sphingolipids influence glucose metabolism in a variety of tissues. Changes in
sphingolipid levels have consequential pathophysiological effects in metabolic syndromes. It has
been observed that diabetic patients have elevated plasma ceramide levels (Borodzicz et al.,
2015). Furthermore, increased levels of ceramide have been shown to result in attenuation of
insulin action, most likely via inhibition of AKT (Hannun and Obeid, 2018; Hla and
Dannenberg, 2012). In a similar manner, other sphingolipids, including sphingomyelin,
glucosylceramide, and other glycosphingolipids, have been shown to inhibit insulin action (Aerts
et al., 2011; Chavez et al., 2014). On the contrary, extracellular S1P carried by high-density
lipoprotein can increase insulin levels by protecting pancreatic islet cells from apoptosis (Rütti et
al., 2009).

Cancer
Sphingolipids have a strong influence in the development and progression of cancer and
have gained attention for their roles in cell death, proliferation, and multi-drug resistance.
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Ceramide can function as a tumor suppressor lipid by potentiating signaling events that drive
apoptosis, autophagic responses and cell cycle arrest (Morad and Cabot, 2013). Total plasma
ceramide has been shown to be a promising biomarker of metastatic tumor response to radiation
therapy (Dubois et al., 2016). However, defects in ceramide generation and metabolism in cancer
cells have been shown to contribute to tumor cell survival and resistance to chemotherapy likely
by neutralizing ceramide or generating pro-survival and mitogenic sphingolipids such as S1P
(Morad and Cabot, 2013). In addition, increased S1P signaling in endothelial cells has been
associated with induction of angiogenesis and inflammatory pathways, thereby contributing to
tumor invasion and metastasis (Hannun and Obeid, 2018; Hla and Dannenberg, 2012).

Inflammation
During inflammation, immune cells are recruited to sites of infection or injury and
activate cytokine networks to protect the host. However, unchecked inflammation can lead to
numerous pathophysiological states such as autoimmune disorders. It has been demonstrated that
circulating S1P is a key regulator of lymphocyte egress (Cyster and Schwab, 2012). S1P is
enriched in lymph and blood compared to interstitial fluids. What’s more, the majority (65%) of
plasma S1P is complexed with Apolipoprotein M (ApoM) (Blaho et al., 2015). ApoM–S1P is
dispensable for lymphocyte trafficking yet restrains lymphopoiesis by activating the S1P1
receptor on bone marrow lymphocyte progenitors. Thus, the signaling axis of ApoM–S1P–S1P1
regulates the lymphocyte emigration from the graining lymph node and adaptive immune
responses (Blaho et al., 2015). High levels of S1P have also been found in patients with
rheumatoid arthritis and with ulcerative colitis (Kitano et al., 2006; Maceyka and Spiegel, 2014).
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Altogether, these roles for S1P signaling in inflammatory and immune disease has led to clinical
trials and FDA-approval of various S1P receptor modulators (Maceyka and Spiegel, 2014).

Neurological disease
In humans, sphingolipid concentrations are highest in the nervous system where their
dysfunction contributes to neurological diseases. Key sphingolipid species are critical for the
normal development and function of brain. Gangliosides, which are heavily glycosylated
sphingolipids, are major components of neuronal membranes and account for 10–12% of the
lipid content in the nervous system (Posse de Chaves and Sipione, 2010). There is evidence that
gangliosides can contribute to the initiation and progression of Alzheimer’s disease by
facilitating plaque formation (Olsen and Færgeman, 2017). Conversely, defective ganglioside
biosynthesis is associated with the development of epilepsy through a loss-of-function mutation
in the monosialodihexosylganglioside 3 (GM3) synthase gene (Fragaki et al., 2013).

Cardiovascular disease
Recent data suggests that specific ceramide species are linked to cardiovascular disease
(Chen et al., 2011). Higher plasma levels of sphingomyelin have been associated with increased
atherosclerosis and have been proposed as independent risk factors for coronary heart disease in
humans (Jiang et al., 2000). Similarly, plasma ceramides have been linked to atherogenesis and
can predict cardiovascular death in patients with stable coronary artery disease and acute
coronary syndromes (Laaksonen et al., 2016). These types of findings have led to the idea that
inhibition of ceramide de novo synthesis could serve as a post-ischemic strategy to reduce
myocardial reperfusion injury (Reforgiato et al., 2016). In contrast, plasma S1P is believed to be
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cardioprotective. Low S1P levels have been associated with impaired cell signaling and ischemic
heart disease, although the exact relation between the two has not been conclusively addressed
(Polzin et al., 2017).

Epigenetic regulation
The human genome is an expanse of genomic loci that contain protein-coding genes and
their regulatory elements, such as promotors and enhancers. Genes are only actively expressed
when they are accessible to regulatory factors and transcriptional machinery, or they are
transcriptionally suppressed within compact and inaccessible structures (Mann et al., 2007).
Epigenetics are inherited traits that are functionally relevant changes to the genome which cannot
be identified by changes in the nucleotide sequence (Figure 1.4). Covalent modifications to
histones and DNA without altering the DNA nucleotide sequence facilitate how cells maintain
“memories” for gene expression patterns (Ronnekleiv-Kelly et al., 2017). These changes can be
maintained through multiple cell divisions or may persist for multiple generations as non-genetic
factors leading to permanent changes in gene expression (McCarrey, 2015). Epigenetic
regulation of gene expression is essential for normal development and cellular function. Changes
in chromatin configuration may cause a wide range of diseases by altering the activity of specific
genes (Brookes and Shi, 2014). Currently, three major mechanisms are thought to be involved in
the epigenetic regulation of gene expression patterns: DNA methylation, histone modification
and non-coding RNAs.
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Figure 1.4. Epigenetic regulation is a dynamic process that occurs above the level of traditional base
pair alterations. Common modifications include acetylation, methylation, phosphorylation, and
ubiquitination. Chromatin remodeling events can be either activating or repressive and occur at the
histone level. Common activating events at the chromatin level include acetylation of histone tails by
histone acetyl transferases (HATs) and removal of methyl groups by histone demethyltransferases
(HDMTs). However, addition of methyl groups by histone methyl transferases (HMT) can also be
activating. These modifications produce an open chromatin state, in which transcription factors can more
easily access the DNA and facilitate gene expression. Common repressive events at the histone level
include removal of acetyl groups by histone deacetylases (HDACs) and addition of methyl groups by
HMTs. Epigenetic control can also be exhibited by direct modifications to nucleotides in certain
sequences, such as CpG islands. Addition of methyl groups by methyltransferases is a repressive mark
and reversal of methylation by demethyltransferases (DMTs) is frequently activating.
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DNA methylation
DNA methylation refers to the addition of a methyl group to cytosine at the 5′-position,
converting it to 5-methylcytosine. DNA methylation is mainly catalyzed by three DNA
methyltransferases (DNMTs): DNMT3A and DNMT3B primarily establish new sites of
methylation whereas DNMT1 maintains existing methylation patterns (Ahuja et al., 2016).
Cytosine methylation within DNA sequences that serve as recognition sites for transcription
factors (TFs) directly can interfere with TF binding or recruit transcriptional repressor
complexes, both of which can repress transcription of genes. Most of our DNA is heavily
methylated, thus DNA methylation is critical for silencing of transcription and resulting in
changes to numerous cellular processes (Azad et al., 2013). Abnormalities in DNA methylation
play a role in pathological processes such as carcinogenesis and oncogenesis. As a result, DNMT
inhibitors are being explored as potential cancer therapies. These inhibitors are cytidine
analogues and work by incorporating into replicating DNA, covalently binding to the catalytic
sites, and inhibiting the enzymatic activities of DNMTs (Azad et al., 2013). To date, two DNMT
inhibitors — azacitidine (also known as 5-azacytidine) and decitabine (also known as 5-aza-2′deoxycytidine), have been approved by the FDA for the clinical treatment of myelodysplastic
syndrome (Pfister and Ashworth, 2017).

Histone modification
Histones are the chief protein components of chromatin that act as spools for DNA to
wind around. Histones affect gene transcription by changing the accessibility of chromatin to
transcription factors and gene expression machinery. They are subject to a wide range of
modifications, including methylation, acetylation, phosphorylation, and ubiquitination (Tan et
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al., 2011). Most studies regarding transcriptional changes with respect to histone modification
have focused on acetylation and methylation (Tough et al., 2016). Histone acetylation primarily
occurs at lysine residues H3K18 and H3K27. The acetylation alters the net charge of histone and
weakens its interaction with DNA leading to a more open chromatin state. The enzymes
responsible for this type of modification are histone acetylases (HATs) and antagonized by
histone deacetylases (HDACs). Overexpression of HDACs is observed in many cancer types,
including prostate, gastric, and endometrial cancers (Tough et al., 2016). Currently, three HDAC
inhibitors are approved by the FDA: vorinostat (also known as SAHA) for the treatment of
cutaneous T cell lymphoma, belinostat for the treatment of peripheral T cell lymphoma, and
romidepsin for the treatment of both cutaneous and peripheral T-cell lymphoma (Campbell and
Thomas, 2017; Smolewski and Robak, 2017).
Histone methylation occurs on both lysine and arginine residues. Methylation of residue
H3K4 acts as a gene enhancer whereas methylation of residues H3K9 or H3K27 represses gene
promoters. Methylation of histones are catalyzed by histone methyltransferases and are removed
by histone demethylases. Specifically, methylation of H3K27 is regulated by Polycomb-group
proteins (PcGs), which are important in many aspects of development like homeotic gene
regulation and X chromosome inactivation (Kassis et al., 2017; Maclary et al., 2017). The
catalytic enzyme in the PcG, EZH2, is upregulated in numerous cancers. Currently, inhibitors of
several histone methyltransferases are being tested in clinical trials, such as inhibitors of EZH2
and DOT1L, although no drugs have been approved in clinical use (Hock, 2012).
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Non-coding RNAs
Non-coding RNA transcripts, RNA transcripts that do not code for translated proteins,
that include microRNAs (miRNAs), piwi-interacting RNAs (piRNAs), circular RNAs
(circRNAs), and long noncoding RNAs (lncRNAs), have a profound epigenetic influence on
transcriptional output of the genome (Wang et al., 2013b). Approximately 50% of miRNA genes
are repressed by epigenetic methylation of their own promoter while other miRNAs are derived
from spliced intronic sequences of coding mRNA (Wang et al., 2013b). After being processed
into mature miRNA and incorporated into the RNA-induced silencing complex (RISC) miRNAs
bind to the 3′-UTR of target mRNAs for degradation. A single miRNA is capable of binding and
degrading multiple mRNAs (Bamezai et al., 2012). Like miRNAs, piRNA associate with the
RISC complex and function as gene silencing mechanism, especially silencing of transposons.
Originally, piRNAs were thought to be expressed exclusively in germline tissue and only play a
biological role in development. Recently evidence has implicated piRNA to be a functional
epigenetic modifier in both germ and somatic stem cell self-renewal as well as tumorigenesis
(Bamezai et al., 2012). Conversely, ciRNA antagonize gene silencing by acting as miRNA
“sponges “or a decoy to miRNA normal target genes and play a key role in disease progression,
especially cancer (Di Ruscio et al., 2013). Lastly, lncRNA have the most dynamic range of
epigenetic regulatory mechanisms that have been characterized to date. Evidence has
demonstrated that lncRNAs have functional roles in chromatin remodeling, X-chromosome
inactivation, RNA splicing, genomic imprinting and DNA methylation (Ahuja et al., 2016; Di
Ruscio et al., 2013; Lee and Bartolomei, 2013; Mercer et al., 2009; Rinn et al., 2007).
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Epigenetic regulators of sphingolipid metabolism
Beyond being lipid components of cellular membranes, sphingolipids mediate signaling
functions in both physiological and pathophysiological processes. Multiple factors including but
not limited to development, environmental chemicals, drugs and diet affect sphingolipid
homeostasis through epigenetic mechanisms (McCarrey, 2015; Wegner et al., 2016).

Development
Gangliosides are a class of glycosylated sphingolipids with one or more sialic acids
bound to a carbohydrate and are particularly abundant in the nervous system (Yu et al., 2009).
During brain development there is a pattern shift of gangliosides from simple to complex species
that is mainly regulated by the stage expression of genes that encode the glycosyltrasferase
enzymes (Tsai and Yu, 2014). A study found that the developmental alteration of gangliosides is
regulated through histone acetylation of the glycosyltransferase enzymes in the mouse brain.
Furthermore, HDAC inhibitors can effectively change the expression patterns of gangliosides
and glycosyltransferases in neuroepithelial cells (Suzuki et al., 2011).

Environmental factors
Hypoxia occurs from stress at high altitude or an otherwise oxygen-depleted
environment. In tissues and cells, hypoxia can occur where blood flow is limited due to various
physiological conditions (Salminen et al., 2016). During hypoxia, hypoxia-inducible
transcription factor-1α (HIF-1α) is expressed to boost energy metabolism and autophagy. Recent
studies found that hypoxia induces the expression of HIF-1α through increased activity of
sphingosine kinase (SPHK). This effect can be blocked by administration of a SPHK inhibitor or
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S1P receptor antagonists (Sanagawa et al., 2016). Stabilization of HIF-1α further increases the
expression of distinct histone lysine demethylases to promote gene expression (Salminen et al.,
2016). Thus, sphingolipid metabolism is closely intertwined with epigenetic changes in
chromatin during hypoxia. Similarly, cigarette smoke has long been proven to induce epigenetic
modifications such as aberrant methylation (Zöchbauer-Müller et al., 2003). It is also the major
cause of chronic obstructive pulmonary disease (COPD) where alveolar macrophages are
defective in their ability to phagocytose apoptotic cells (Barnawi et al., 2017). A study identified
that cigarette smoke extract significantly increased expression of S1P receptor 5 (S1PR5). In
alveolar macrophages from COPD patients, the expression levels of S1PR5 is significantly
increased and is correlated with defective efferocytosis (Barnawi et al., 2015). They further
found that this dysregulation of S1P signaling system is caused by reduced DNA methylation of
the S1PR5 gene. In this way, decreased promoter methylation released gene transcription of
S1PR5, which is essential for S1P-mediated clearance of apoptotic cells (Barnawi et al., 2015).

Drugs
Neutral sphingomyelinase 2 (nSMase2) is a key ceramide-producing enzyme in cellular
stress responses. Tretinoin, also known as all-trans retinoic acid (ATRA), is medication used for
the treatment of acute promyelocytic leukemia (APL) (Abaza et al., 2017). Although the
mechanism of action is still unknown, studies have demonstrated that tretinoin encourages
progenitor cells in APL patients to differentiate terminally and thereby ameliorating the
progression of the disease (Nitto and Sawaki, 2014). A recent study identified nSMase2 as an
early ATRA-induced gene and implicated nSMase2 having a role in growth arrest after ATRA
treatment (Clarke et al., 2016). Furthermore, it was found that ATRA regulates nSMase2 directly
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through modulation of histone acetylation in a CREB-binding protein and p300 dependent
manner (Clarke et al., 2016).
Mesenchymal stem cells (MSCs) are multipotent progenitor cells that can be used to
improve tissue repair. Current MSC therapies are often primed with bioactive lipids such as S1P
and ceramide-1-phosphate, which can enhance in vivo engraftment and survival of transplanted
cells (Ratajczak et al., 2010). A recent study found that the HDAC inhibitor valproic acid (VPA)
enforced the priming effect of S1P at a low dosage in human umbilical cord derived MSCs
through the activation of the MAPK and AKT signaling pathways (Kim et al., 2013). This study
indicated that the combinatory effects of epigenetic modulators and S1P-priming strategies can
improve the therapeutic potency of stem cells. Similarly, VPA has been found to induce the
generation of glycosphingolipid GM3, a known suppressor of epidermal growth factor receptor
phosphorylation to suppress cancer cell proliferation (Kawashima et al., 2016). Additionally,
another HDAC inhibitor, AR-42, has been shown to exert an anti-colon cancer activity through a
mechanism of ceramide production (Xu et al., 2015).

Toxins
Fumonisin B1 (FB1) is a Fusarium mycotoxin frequently occurring in maize-based food
and feed. Importantly, FB1 is a well-recognized inhibitor of de novo ceramide synthesis due to
its ability to inhibit (dihydro)ceramide synthase activity. Intriguingly, FB1 may lead to liver
tumorigenesis by disrupting DNA methylation and chromatin modifications which causes
chromatin instability in HepG2 cells (Chuturgoon et al., 2014; Demirel et al., 2015).
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Sphingolipids as epigenetic regulators
As mentioned, bioactive sphingolipids serve both as structural lipids and signaling
molecules. Aside from prominent roles associated with being located on the plasma membrane,
sphingolipids and their metabolizing enzymes are also found in the nucleus and associated with
the nuclear matrix and chromatin. Their metabolism in the nucleus has been linked to remodeling
of chromatin and epigenetic regulation of gene expression (Spiegel et al., 2012).

S1P
S1P was the first identified endogenous nuclear regulator of HDACs. In human MCF-7
breast cancer cells, S1P in the nucleus was found to specifically bind to the HDAC1 and HDAC2
and inhibited their enzymatic activity (Hait et al., 2009). Another study in dystrophic mice
revealed that expression of S1P increased histone acetylation of specific genes, in which
inflammatory genes are downregulated while metabolic genes are upregulated, helping muscle
cells maintain energy metabolism (Nguyen-Tran et al., 2014). Additionally, in drosophila of
Duchenne muscular dystrophy, S1P was found to increase the capacity of the muscle cell to use
fatty acids as an energy source by inhibiting the acetylation of specific histone residues (NguyenTran et al., 2014). Thus, nuclear S1P can be directly linked to epigenetic regulation of gene
expression by modulating histone acetylation. In a somewhat contrasting manner, the
degradation of S1P by the S1P lyase has also been attributed to the regulation of sepsis-mediated
inflammation. This was attributed to S1P degradation products serving as regulators of histone
acetylation (Ebenezer et al., 2017).
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Ceramide
Inhibitor 2 of protein phosphatase 2A (I2PP2A) is a biological inhibitor of the cellular
serine/threonine protein phosphatase PP2A (Dent, 2013; Mukhopadhyay et al., 2013). I2PP2A
has been suggested to be oncogenic and has been shown to be overexpressed in many tumor cell
types. I2PP2A also has other targets besides PP2A, e.g., DNA exonucleases and the modification
of histone acetylation. It has been shown that ceramide can disrupt the association between PP2A
and I2PP2A. Additionally, ceramide inhibits I2PP2A’s upregulation of c-Myc and its
downregulation of histone acetylation in prostate cancer cells, blocking the epigenetic action of
I2PP2A (Mukhopadhyay et al., 2013). Conversely, in Madin-Darby canine kidney cells,
sphingomyelin-derived ceramide has also been shown to inhibit the deacetylation of
microtubules which induces formation of a ciliogenic lipid-protein complex that can sustain
primary cilia (He et al., 2012). This may not be directly epigenetic in nature but involves the
regulation of a post-translational modification that also can play a role in epigenetics.

Gangliosides
Gangliosides are expressed primarily on the outer leaflet of the plasma membrane of cells
in all vertebrates, and are most abundant in the nervous tissues (Tsai et al., 2016). Studies have
provided evidence that ganglioside GM1 is associated with gene regulation in neuronal cells
through an interaction with active chromatin via acetylated histones (Itokazu et al., 2017).
Ganglioside GM1 was found to bind to acetylated histones H3 and H4 on the promoters of the
GalNAcT and NeuroD1 genes. This interaction was shown to activate neuronal differentiation in
neural stem cells, and was further supported by exogenous supplementation of ganglioside GM1
(Itokazu et al., 2017; Tsai et al., 2016).
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Sulfatide
Sulfatide also is a glycosphingolipid. In hepatocellular carcinoma cells, it has been found
to suppress miR-223 expression in association with reduced recruitment of acetylated histone H3
and C/EBPα to the pre-miR-223 gene promoter. Sulfatide was also shown to stimulate the
expression of histone deacetylases HDAC9 and HDAC10, and enhance their recruitment to the
miR-223 gene promoter (Dong et al., 2014).

Concluding thoughts
Sphingolipid metabolism and epigenetic modulation are closely intertwined with one
another. Epigenetic regulation is an important regulatory mechanism for controlling the
expression pattern of sphingolipids. Conversely, sphingolipids in the nucleus can directly
modulate transcriptional activity via epigenetic modulation. An understanding of both processes
is critical as they play an integral role in both normal development and pathological processes. A
deeper investigation into how sphingolipid metabolism influences epigenetic regulation, and the
reciprocal relationship, in the context pathophysiology of disease development can potentially
lead to new diagnostics and therapeutic targets (Hannun and Obeid, 2018).
Future studies of the relationships between epigenetics and sphingolipid metabolism
should address the following questions: 1) what other sphingolipids can directly influence
epigenetic regulation, 2) how can aberrant epigenetic regulation and sphingolipid metabolism
contribute to the development of cancer and other diseases, and 3) what are the mechanisms that
dictate the interplay between epigenetic and sphingolipid metabolic regulation? Investigation of
these questions may yield results that could contribute to the advancement of biomedical
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research and the development of the next generation of molecular and sphingolipid-targeted
therapies.
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1.4. Therapeutic Potential of Ceramides in Cancer Treatment3

Abstract
Ceramides are a family of wax-like lipids that fall under the broader category of
sphingolipids. A ceramide molecule is composed of a sphingosine side chain linked to a fatty
acid via an amide group. Distinct from other sphingolipids, the head of the ceramide sphingosine
side group is a simple alcohol rather than a sugar or phosphocholine linkage. The fatty acid
chains of ceramide can vary in chain length and degree of saturation. The degree of saturation
determines the biological activity of the ceramide (Ventura et al., 2019). Shorthand nomenclature
for these backbones include a “d” or “t” to indicate the number of hydroxyl groups followed by
the acyl chain length and number of double bonds as seen in fatty acids. For instance,
sphingosine can be written as d18:1 (Pruett et al., 2008). Ceramides are highly abundant within
the cell membrane of eukaryotic cells and are classically appreciated for their role as structural
elements. More recently, ceramides are being appreciated for their biological activity as well.
They have been found to participate in a variety of cellular pathways including apoptosis, cell
senescence, the cell cycle, and cell differentiation (Holthuis et al., 2001). This review discusses
pathways of ceramide synthesis and metabolism, roles of ceramide in different diseases,
targeting ceramide metabolism in the treatment of cancer, as well as ceramide-delivering
nanotechnologies.

3

Weiyuan Wang, Bert F. Prince, Alexander J. Thorpe, Brian M. Barth. Therapeutic Potential of Ceramides in
Cancer Treatment. In preparation for submission.
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Ceramide Metabolism
Ceramide metabolism is a complex network of interconnected pathways with many
origins (Figure 1.5). Broadly, ceramide metabolism can be classified into de novo synthesis and
catabolism, including recycling, salvage, and degradation.

Figure 1.5. Pathway for ceramide synthesis and metabolism. De novo ceramide synthesis initially
generates dihydrosphingoid species prior to desaturation. Salvage ceramide synthesis, or turnover by the
successive activities of acidic/lysosomal-localized catabolic enzymes, generates sphingosine that escapes
the lysosome to be re-acylated to ceramide. Glucosylceramide synthase (GCS); cerebrosidase (GBA);
sphingomyelin synthase (SGMS); ceramide kinase (CERK), ceramide-1-phosphate phosphatase (C1PP);
ceramidases (CDase); ceramide synthase (CERS); sphingosine kinase (SPHK); S1P phosphatase (S1PP).
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De novo synthesis
De novo synthesis of ceramide occurs in the endoplasmic reticulum. It starts with the
condensation of a serine residue and a palmitoyl-CoA by serine palmitoyltransferase, which
produces 3-keto-dihydrosphingosine. This unstable intermediate is rapidly reduced to
dihydrosphingosine (also known as sphinganine) by 3-ketosphinganine reductase. The ceramide
synthase (CERS) family catalyzes the N-acylation of dihydrosphingosine into dihydroceramide.
Desaturase then introduces a 4,5-trans-double bond into the sphinganine backbone of
dihydroceramide, producing a complete ceramide molecule.
Six ceramide synthases (CERS1-6) have been identified in humans (Table 1.2). Each
CERS enzyme prefers different chain lengths of the fatty acyl-CoA substrate involved in the Nacylation of dihydrosphingosine. The resulting dihydroceramide will contain a fatty acid of
varying lengths depending on the CERS enzyme used. The chain lengths of the fatty acyl-CoA
used will vary from 14 to 36 carbons. Ceramides with different chain compositions impact cell
physiology differently (Pinto et al., 2014). In addition, different ceramide synthases have
different tissue distribution patterns. For example, CERS1 is most highly expressed in the brain
and skeletal muscle, which correlates with an abundance of C18 ceramide in those tissues.
CERS2 is most highly expressed in the liver and kidneys and favors long chain fatty acids
(C22:0-24:0) (Wattenberg, 2018). CERS3 is highly expressed in the skin and testis and is highly
selective toward very-long (C22:0-C24:0) and ultra-long (more than C26:0) chains. CERS4 is
highly expressed in the skin and leukocytes and catalyzes formation of ceramide with a high
selectivity towards long and very-long chains (C18:0-C22:0) (Kihara, 2012). CERS5 is more
commonly found in the muscle and brain. It prefers short chain fatty acyl-CoA and mainly
produces ceramides incorporating C16:0 fatty acyl-CoA (Wattenberg, 2018). CERS6 also uses
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C16:0 fatty acyl-CoA as a substrate and is most commonly found in the brain (Kitatani et al.,
2008).

Table 1.2. Classification and distribution of ceramide synthases
Ceramide synthase

Chain length of the fatty acyl-CoA substrate

CERS1
CERS2
CERS3
CERS4
CERS5
CERS6

C18
C22-C24
C22-C24, > C26
C18-22
C16
C16

Tissue distribution
Brain and skeletal
muscle
Liver and kidneys
Skin and testis
Skin, leukocytes
Muscle and brain
Brain

Salvage, recycling, and degradation
In addition to the de novo synthesis, ceramide can be “salvaged” from complex
sphingolipid reservoirs, recycled into other sphingolipids, or degraded into simple molecules.
These three pathways, alongside with de novo synthesis, regulate the cellular levels of ceramide.
The salvage of ceramide from larger sphingolipids provides for more than half of
ceramide biosynthesis. One such example is the catabolism of glycosphingolipids. During the
breakdown of large glycosphingolipids, sugar groups are cleaved off which leads to the
formation of either glucosylceramide or galactosylceramide. In turn, specific β-glucosidases and
galactosidases hydrolyze these lipids to form ceramide (Kolter and Sandhoff, 2005). In addition
to the formation of ceramide from larger sphingolipids such as glycosphingolipids, ceramide can
be formed via the hydrolysis of sphingomyelin by acid sphingomyelinase (aSMase) (Wattenberg,
2018). Ceramide can also act as a substrate to build more complex sphingolipids. For instance,
ceramide can be converted into sphingomyelin, a large component of the fatty myelin sheath, via
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the action of sphingomyelin synthase (SGMS). Similarly, ceramide can be acted on by
glucosylceramide synthase (GCS) to form glucosylceramide. GCS is an enzyme that in humans
is encoded by the UGCG gene. These new substrates can go on to form more complex
sphingolipids in the Golgi apparatus, an example of which would be gangliosides. These
products are then transported to the plasma membrane, the major reservoir of these lipids
(Hanada et al., 2003; Maceyka and Spiegel, 2014). The degradation of ceramide is also a
necessary part of maintaining lipid homeostasis. Ceramides present in endothelial cells are
deacylated by acid ceramidase to form sphingosine, the center of sphingolipid metabolism. It
eventually results in the hydrolysis of triglycerides and phospholipids and shedding of some of
the surface components (Hussain et al., 2012).

Ceramide and Sphingosine-1-phosphate
In addition to ceramide, sphingosine-1-phosphate (S1P) is an important sphingolipid to
highlight. Ceramide can be converted into S1P via two enzymatic reactions. First, ceramidase
(CDase), typically acid CDase, converts ceramide to sphingosine and then sphingosine kinase
(SPHK), typically SPHK1, phosphorylates sphingosine to S1P. Although S1P and ceramide
share structural similarities and are easily interconverted, the two exhibits opposite effects.
Whereas ceramide is well appreciated for its role in the stimulation of apoptosis, S1P is
appreciated as a pro-survival signal, leading to increased cell growth and viability (Ogretmen,
2018). S1P’s pro-survival effects are beneficial to tumors and thus an excess of S1P in tissues is
associated with tumor neogenesis. S1P signals through G-protein coupled receptors (GPCRs)
known as S1P receptors (S1PRs). Activation of S1PRs often leads to subsequent activation of the
Raf-Mek-Erk pathway, a classic mitogenic pathway. Thus, activation of these GPCRs leads to
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increased tumor cell viability. The control of the titer of ceramide and S1P in tumors is thought
to be a potential therapeutic target (Wang et al., 2018).

Roles of ceramides in diseases
Structurally diverse ceramides can provide platforms for signaling events and
protein/lipid trafficking along cellular membranes (Bieberich, 2018). Thus, changes in ceramide
levels can alter the biophysical properties of the membrane. In this way, ceramide functions as a
sensor and affects the distribution of transmembrane proteins and other cellular responses
(Ventura et al., 2019). Consequently, abnormalities in ceramide homeostasis can lead to various
diseases.

Skin diseases
Skin ceramide composition, which plays crucial roles in maintaining the barrier function
of the stratum corneum, is changed in patients with atopic dermatitis (Shen et al., 2018). It is
accompanied by a change of ceramide synthase isoform expression from CERS3 to CERS4,
leading to a barrier repair response (Peters et al., 2020). Topical treatment with pseudo-ceramide
lotion, which contains 3% of Cetyl-PG hydroxyethyl palmitamide, has been found to
significantly reduce skin symptoms. Additionally, a significant decrease in trans-epidermal water
loss and increased water content has been shown with pseudo-ceramide treatment. Those
changes are associated with a distinct switch of the ceramide profile from an atopic dermatitis to
a healthy skin phenotype without any increased level of endogenous ceramides (Ishida et al.,
2020). Increased ceramide content results in acceleration of epidermal barrier restoration after
acute skin damage (Shin et al., 2020).
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Metabolic syndrome
Ceramides contribute to lipotoxicity that underlies metabolic syndrome and related
diseases such as type 2 diabetes and cardiovascular disease (Fang et al., 2019). The species of
ceramide that are associated with cardiovascular disease progression are C16 ceramide
(d18:1/16:0), C18 ceramide (d18:1/18:0), and C24:1 ceramide (d18:1/24:1). These ceramides
lead to abnormalities in glucose metabolism by blocking insulin signaling. Additionally, these
ceramides dysregulate lipid metabolism by promoting adipose inflammation. The C24 ceramide
(d18:1/24:0) species has been associated with good cardiovascular health (Poss et al., 2019). It
has been found that daily oral treatment with P053, which specifically targets CERS1, promotes
skeletal muscle fatty acid oxidation and reduces whole-body fat accumulation without causing
insulin resistance (Turner et al., 2018).

Infections and Inflammation
Different properties of structural domains formed by ceramides can cause changes in
membrane curvature. These changes in membrane morphology may be exploited by pathogens,
leading to easier host cell infection (Prévost et al., 2015). Bile acids and ceramides have been
found to allow for the entry of viruses and to facilitate their subsequent replication in jejunal
enteroids. Some viral pathogens invade the epithelial barrier and replicate in the human small
intestine. Ceramide assists their release into the cytoplasm by acting as an initial binding factor
for norovirus strains (Murakami et al., 2020). Conversely, it has also been found that ceramide
can mediate a neutrophil extracellular trap formation to boost bactericidal capacity in neutrophils
(Corriden et al., 2015).
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Cancers
Ceramides of specific chain lengths have been found to be dysregulated in various cancer
types, either mediating apoptosis via mitochondrial membrane perturbation and/or influencing
cell death signaling or having protective roles against apoptosis (Ogretmen, 2018). The exact
effect of ceramide on cancer depends on the specific ceramide structure and the cellular context
(Jeffries and Krupenko, 2018). For example, C16 ceramide generation is decreased in human
ovarian carcinoma cells (Prinetti et al., 2006). Overexpression of CERS2, which increased the
generation of C24 ceramide, protected Hela cells from ionizing radiation (IR)-induced apoptosis
(Mesicek et al., 2010). However, C14 ceramide, C16 ceramide, and C18 ceramide levels are
significantly increased in breast cancer tissue compared to the normal tissue suggesting a
contrast in function of ceramide in different cancers (Moro et al., 2018). Notably, various
anticancer therapeutics have been shown to alter the levels of cellular ceramides (Table 1.3).

Table 1.3. Anti-cancer therapeutics that affect ceramide generation
Name of the
anti-cancer
therapeutics

Mechanism of
action

Effects on
ceramide
expression

Cancer types

Citations

Chemotherapy agents
Sorafenib

Kinase inhibitor
against VEGFR,
PDGFR and Raf
kinases.

Increase CERS1
expression

Acute myeloid
leukemia

(Dany et al.,
2016)

Quizartinib

Tyrosine kinase
inhibitor against
FLT3/STK1,
CSF1R/FMS,
SCFR/KIT, and
PDGFRs

Increase CERS1
expression

Acute myeloid
leukemia

(Dany et al.,
2016)
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Table 1.3. Continued
Name of the
anti-cancer
therapeutics

Mechanism of
action

Effects on
ceramide
expression

Cancer types

Citations

Chemotherapy agents
Crenolanib

Tyrosine kinase
inhibitor against
FLT3, PDGFRα
and PDGFRβ

Increase CERS1
expression

Acute myeloid
leukemia

(Dany et al.,
2016)

Imatinib

Tyrosine kinase
inhibitor against
Bcr-Abl

Increase CERS1
expression

Chronic
myelogenous
leukemia

(Baran et al.,
2007)

Dasatinib

Tyrosine kinase
inhibitor against
Bcr-Abl

Increase CERS1, Chronic
CERS5, CERS6 myelogenous
expression
leukemia

(Gencer et al.,
2011)

Doxorubicin

Interfering with
the function of
DNA

Increase CERS1, Embryonic
CERS2, CERS5 kidney cells,
expression
Bladder cancer,
Breast cancer

(Fan et al., 2013;
Huang et al.,
2018; Min et al.,
2007)

Cinobufotalin

Inducing growth
inhibition and
apoptosis

Increase CERS1
expression

Hepatocellular
carcinoma

(Cheng et al.,
2015)

Aburs agglutinin

Inactivating
Increase CERS1
Type II ribosome expression

Glioblastoma

(Panda et al.,
2018)

Teniposide

Inhibitor of
topoisomerase II

Increase CERS1
expression

Glioma

(Wang et al.,
2017)

Cisplatin

Interfering with
DNA replication

Increase CERS1, Embryonic
CERS6
kidney cells,
expression
Oral squamous
carcinoma
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(Li et al., 2018;
Min et al., 2007)

Table 1.3. Continued
Name of the
anti-cancer
therapeutics

Mechanism of
action

Effects on
ceramide
expression

Cancer types

Citations

Chemotherapy agents
Carboplatin

Interfering with
DNA replication

Increase CERS1
expression

Embryonic
kidney cells

(Min et al.,
2007)

Vincristine

Inhibitor of
mitosis at
metaphase

Increase CERS1, Embryonic
CERS5
kidney cells
expression

(Min et al.,
2007)

Oxaliplatin

Inhibiting DNA
synthesis

Increase CERS5
expression

(Brachtendorf et
al., 2018)

Etoposide

Inhibiting DNA
synthesis

Increase CERS2, Embryonic
CERS3, CERS4 fibroblasts
expression

(Siddique et al.,
2012)

Fluorouracil (5FU)

Inhibiting DNA
replication

Decrease CERS5 Colon cancer
expression

(Brachtendorf et
al., 2018)

Dorsomorphin

Inhibitor of BMP Increase CERS5
signaling
expression

Breast cancer

(Jin et al., 2009)

Methotrexate

Inhibiting the
synthesis of
DNA, RNA,
thymidylate, and
protein

Increase CERS6
expression

Liver cancer,
Lung cancer

(Fekry et al.,
2016)

Daunorubicin

Inhibiting DNA
synthesis

Increase CERS
expression

Leukemia

(Bose et al.,
1995)

Fludarabine

Inhibiting DNA
synthesis

Increase CERS2
expression

Chronic
lymphocytic
leukemia

(Biswal et al.,
2000)
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Colon cancer

Table 1.3. Continued
Name of the
anti-cancer
therapeutics

Mechanism of
action

Effects on
ceramide
expression

Cancer types

Citations

Chemotherapy agents
Gemcitabine

Inhibiting DNA
synthesis

Increase CERS2
expression

Pancreatic
cancer

(Modrak et al.,
2009)

Camptothecin

Inhibiting DNA
synthesis

Increase de novo
ceramide
synthesis

Follicular
thyroid
carcinoma

(Rath et al.,
2009)

Irinotecan

Inhibiting DNA
synthesis

Block formation
of glucosylceramide

Colorectal
cancer

(Litvak et al.,
2003)

UV-B radiation

Damaging DNA

Increase CERS1
expression

Lung cancer

(Sridevi et al.,
2009)

Ionizing
radiation

Damaging DNA

Increase CERS2, Cervical cancer
CERS5, CERS6
expression

(Mesicek et al.,
2010)

Increase CERS2, Glioma
CERS6
expression

(Jensen et al.,
2014)

Decrease
CERS4, CERS5
expression

(Mojakgomo et
al., 2015)

Radiation

Alternative medicine
Staurosporine

Inhibitor of
protein kinases
against PKC

Hormone inhibitors
Anastrozole

Blocking the
production of
estrogens
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Endometrial
cancer

Table 1.3. Continued
Name of the
anti-cancer
therapeutics

Mechanism of
action

Effects on
ceramide
expression

Cancer types

Citations

Breast cancer

(Wang et al.,
2003)

Hormone inhibitors
Tamoxifen

Selective
Inhibit ceramide
estrogen receptor glycosylation
modulator

Adjuvant drugs
Tetrahydrocanna
binol (THC)

Partial agonist
activity at
cannabinoid
receptors

R(+)Synthetic longmethanandamide lasting
anandamide
analog

Increase CERS5, Glioma
CERS6
expression

(HernándezTiedra et al.,
2016)

Increase CERS6
expression

Mantle cell
lymphoma

(Gustafsson et
al., 2009)

Increase CERS6
expression

Colon cancer

(Schiffmann et
al., 2010)

Anti-inflammatory drugs

Celecoxib

COX-2 inhibitor

Drugs in clinical trials
Stichoposide D

Inducing
apoptosis

Increase CERS6
expression

Leukemia

(Yun et al.,
2015)

Cladososide C2

Inducing
apoptosis

Increase CERS6
expression

Leukemia

(Yun et al.,
2015)

TRAIL(Apo-2L)

Inducing TNFrelated apoptosis

Increase CERS6
expression

Colon cancer

(WhiteGilbertson et al.,
2009)
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Table 1.3. Continued
Name of the
anti-cancer
therapeutics

Mechanism of
action

Effects on
ceramide
expression

Cancer types

Citations

Drugs in clinical trials
IL-24

Inducing
apoptosis and
angiogenesis

Increase CERS6
expression

Glioblastoma

(Yacoub et al.,
2010)

Resveratrol

Not yet clear

Inhibition of
dihydroceramide
desaturase

Gastric cancer

(Signorelli et al.,
2009)

Fenretinide

Inducing
apoptosis

Activate serine
palmitoyl
transferase

Prostate cancer

(Wang et al.,
2003)

Targeting ceramide metabolism for cancer therapy
Considering the known effects of ceramide and its dysregulation in many cancers,
developing ceramide-based therapies for cancers is very attractive. Various therapies have aimed
to target ceramide metabolism as a method to control apoptosis in cancer cells (Table 1.4). These
therapies upregulate endogenous production of ceramides or downregulate ceramide
neutralization enzymes. Enzymes that neutralize ceramide convert ceramide to non-ceramide
sphingolipids. Examples include SGMS and CDase (Figure 1.5). The goal of these therapies is to
raise the intracellular concentration of ceramide to direct cancer cells towards apoptosis. In
addition to augmenting endogenous ceramide synthesis via pharmacological interventions,
increasing ceramide levels through exogenous analogs has been widely explored in various
cancer models. Various analogs or inhibitors of ceramide signaling have also shown efficacy in
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clinical trials. Ceramides are not the only sphingolipids that are being explored for their potential
to treat cancers. For example, Fingolimod (FTY720), a structural analog of S1P, has been
approved for clinical use in the treatment of multiple sclerosis and has also shown efficacies in
treatments of cancer (Chun and Hartung, 2010). Mechanistically, Fingolimod suppresses tumor
growth via S1PR-dependent or receptor-independent mechanisms in colon and lung cancer,
respectively (Liang et al., 2013; Saddoughi et al., 2013). It has also shown potential to treat
imatinib-refractory chronic myeloid leukemia by inhibiting stem cell proliferation and expansion
in vitro (Neviani et al., 2013).

Table 1.4. Synthetic drugs that target ceramide metabolism
Synthetic
drugs

Mechanism of
action

Effective cancer types

Analog 315
and 403

Ceramide analog

Primary effusion lymphoma, (Chen et al., 2020)
breast cancer

Analog 406

C8-Ceramide analog

Breast cancer, ovarian
cancer

(Ponnapakam et al.,
2014)

LCL30

C16-Ceramide
analog

Squamous carcinoma

(Separovic et al.,
2011)

C16-serinol

C16-Ceramide
analog

Neuroblastoma

(Bieberich et al., 2000)

LCL85

C16-Ceramide
analog

Colon carcinoma

(Paschall et al., 2014)

LCL29

C6-Ceramide analog

Squamous carcinoma

(Separovic et al.,
2011)

LCL85

C16-Ceramide
analog

Colon cancer, breast cancer

(Paschall et al., 2014)

LCL124

C6-Ceramide analog

Pancreatic cancer

(Beckham et al., 2013)
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Citations

Table 1.4. Continued
Synthetic
drugs

Mechanism of
action

Effective cancer types

Citations

LCL204

Inhibitor of
ceramidase

Head and neck squamous
cell cancers

(Elojeimy et al., 2007)

D-MAPP, B13

Inhibitors of
ceramidase

Colon cancer

(Selzner et al., 2001)

Ceranib-2

Inhibitor of
ceramidase

Mammary adenocarcinoma

(Draper et al., 2011)

LCL385

Inhibitor of
ceramidase

Prostate tumors

(Mahdy et al., 2009)

LCL521

Inhibitor of
ceramidase

Squamous cell carcinoma

(Korbelik et al., 2016)

Fingolimod

Structural analog of
S1P

Colon cancer, lung cancer,
chronic myeloid leukemia

(Liang et al., 2013;
Neviani et al., 2013;
Saddoughi et al.,
2013)l

SK1-I

Inhibitor of SPHK1

Glioblastoma

(Kapitonov et al.,
2009)

PF-543

Inhibitor of S1P

Head and neck carcinoma,
colorectal cancer

(Ju et al., 2016;
Schnute et al., 2012)

VPC03090

S1PR 1/3 antagonist

4T1 mammary carcinoma

(Kennedy et al., 2011)

AB1

S1PR 2 antagonist

Neuroblastoma

(Li et al., 2015)

Sonepcizumab

S1P antibody

Renal cell carcinoma

(Pal et al., 2017)

ABC294640

Inhibitor of
sphingosine kinase 2

Pancreatic cancer, prostate
cancer, advanced solid
tumors, multiple myeloma,
lymphoma

(Britten et al., 2017;
Lewis et al., 2016; Qin
et al., 2014; Venant et
al., 2015; Venkata et
al., 2014)
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Nanotechnology for ceramide delivery
One of the issues with ceramide-based therapies is the delivery of the drug to appropriate
body tissues. Since ceramide is highly hydrophobic, a suitable carrier is needed for its successful
delivery without restricting its pharmacological effects. Recently, delivering drugs via
nanotechnology has become more appreciated. Nanoparticles, measuring up to 400 nm in size,
have demonstrated efficacy for carrying and delivering therapeutic molecules with diverse
physiological properties. Several delivery materials have been explored to increase the drug
performance (Table 1.5). Importantly, the use of nanoparticles may allow for selective targeting
of tumors due to the enhanced permeation retention (EPR) effect. The EPR effect is the
propensity of tumor vasculature to be leaky. This is largely due to the disorganized manner in
which tumor-mediated neovascularization occurs. Gaps between vascular endothelium provides
potential for targeting of anti-cancer therapies to specific tissues. Nanoparticles are small enough
to leave the vasculature at points of disorganization and leakiness. In theory, this facet of tumors
would allow for specific targeting of cancerous tissues by nanomedicines (Kester et al., 2015). A
particularly optimistic facet of nanotechnology usage in ceramide delivery is the potential for
non-toxic therapies. One of the largest issues in cancer therapeutics is the toxic nature of many of
the drugs used to treat cancer. Unlike many standards of care therapeutics, the C6-ceramide
nanoliposome has shown promising results in terms of toxicity. In dog and murine models, the
C6-ceramide nanoliposome was minimally toxic (Kester et al., 2015). The use of
nanotechnology in drug delivery may lead to a new generation of cancer therapeutics, one in
which toxicity is not the norm for standard of care therapies.
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Table 1.5. Nanotechnology for ceramide delivery
Delivery materials
C6-Ceramide
Nanoliposome

Advantages

Citations

Overcome the lack of solubility in physiological (Stover and
solutions, limited cell permeability and circulating Kester, 2003)
catabolic enzymes

Poly(D,L-lactide-coglycolide) PLGA

Exhibit favorable performances in anticancer drug (Graf et al.,
delivery but insufficient tumor targetability
2012)

Polyethyleneglycolchitosan-ceramide

Have sustained release and higher cellular uptake
but lower cytotoxicity

(Battogtokh and
Ko, 2014a)

Solid lipid
nanoparticles

Provide large surface area and high loading
content for hydrophobic drugs, have better
stability

(Balakrishnan et
al., 2016)

Chitosan-ceramide
graft copolymer

Improve the stability and reduce toxicity under
physiological conditions

(Battogtokh and
Ko, 2014b)

Combined usage of ceramide and other drugs in the treatment of cancer
With the application of nanotechnology, exogenous ceramides are being explored in
various cancers. C6-ceramide has been found to prevent metastasis and recurrence of anaplastic
thyroid carcinoma cell lines (Fujiwara et al., 2020). The C6-ceramide nanoliposome slows the
growth of liver tumors in mice by boosting T-cell activity (Bai and Guo, 2018). In addition to
being administered alone, exogenous ceramide can also be incorporated with other drugs into
innovative cancer treatments (Moro et al., 2019). The nanoliposome shows potential as a
delivery mechanism of such therapies because ceramide can be easily distributed into the
hydrophobic membrane of the nanoliposome, and hydrophilic therapies can be placed into the
aqueous interior of the nanoliposome. As emerging studies have shown that ceramide can
77

influence other drugs through nanoparticles, ceramide will probably have more significant
clinical application in combination with chemotherapy (Table 1.6).

Table 1.6. Combination of ceramide and other drugs in the treatment of cancer
Combination usage

Cancer types

Citations

Curcumin + C6-ceramide

Melanoma

(Yu et al., 2010)

Curcumin + C6-ceramide

Osteosarcoma

(Dhule et al., 2014)

Vinblastine + C6-ceramide

Hepatocarcinoma and colorectal
cancer

(Adiseshaiah et al., 2013)

Sorafenib + C6-ceramide +
C8-ceramide

Melanoma and breast cancer

(Tran et al., 2008)

Safingol + C2-ceramide

Acute myeloid leukemia

(Tan et al., 2014)

Doxorubicin + C6-ceramide

Breast cancer and melanoma

(Fonseca et al., 2014)

Myrisplatin + C6-ceramide

Ovarian cancer

(S et al., 2014)

Paclitaxel + C6-ceramide

Melanoma

(Carvalho et al., 2017)

Gemcitabine + C6-ceramide Pancreatic cancer

(Jiang et al., 2011)

PDMP + C6-ceramide

(Jiang et al., 2011)

Pancreatic cancer

Conclusions
Sphingolipids, and other lipids as well, have been classically appreciated as being
structural elements of cells. While this is a truism, it is not the whole picture. Biologically active
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lipids play vital roles in the development and prevention of diseases. This is highlighted through
an examination of ceramides, their metabolic pathways, and their demonstrative physiological
effects. Ceramides play large roles in many disease processes. One disease that is highly
associated with ceramides is cancer. Many cancers experience a downregulation of ceramides
and the enzymes responsible for the biosynthesis of ceramides. This is because the presence of
large quantities of endogenous ceramides leads to the induction of apoptosis. Interestingly a
highly-related sphingolipid, S1P, is highly bioactive but acts to achieve the opposite
physiological effect of ceramide, that is an increase in mitogenic and cell survival signaling.
Ceramides have antitumor therapeutic potential through their role in the stimulation of both
mitochondrial mediated and death-receptor mediated apoptosis. The question of how to exploit
this effect of endogenous ceramides is yet to be definitively answered. Some drugs, as mentioned
above, have aimed to control the metabolism of ceramide. The result of these therapies is an
increased abundance of intracellular ceramide. They do this primarily by downregulating
ceramide neutralization enzymes, which are responsible for the conversion of ceramide to nonceramide sphingolipids. Within this category of therapeutics, therapies that aim to downregulate
the activity of sphingosine-1-phosphate, such as AB1 and Sonepcizumab should be considered as
well because they act to manipulate sphingolipid metabolism to combat cancers. As S1P’s
activity yields an opposite physiological effect of ceramide, the antagonism of S1PRs has
therapeutic potential. Other drugs have instead focused on introducing exogenous ceramides to
cancer tissues. Although the goal of the therapies is similar, these do not involve control of the
metabolism of tumor cells. In many ways this is a more direct way of raising the intracellular
levels of ceramide, but there are issues that need to be solved before these therapies can be
brought to the bedside. Such therapies have had troubles finding effective and targeted methods
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to deliver exogenous ceramides. The development of delivery systems such as the nanoliposome
provide optimism for the next generation of cancer therapeutics. Through such delivery methods,
there is real potential for less toxic and more efficacious therapies such as novel ceramide-based
drugs. Although a promising field, ceramide-based therapies have a way to go until they are
standard of care. New approaches to delivery will need to be developed to solve existing issues
such as drug loading and non-specific tissue targeting. It is hoped that in time these novel
ceramide-based therapies will efficiently treat a variety of malignancies.
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1.5. Regulation of Growth/Differentiation Factor 1 in Human and Animals

Abstract
Growth/differentiation factor 1 (GDF1) is a protein that in humans is encoded by the
GDF1 gene. It is a member of the transforming growth factor-beta (TGFb) superfamily, which
encompasses a large group of structurally related polypeptides that regulate cell growth and
differentiation. GDF1 is mainly found in the brain, spinal cord and peripheral nerves of embryos.
It has a role in left-right patterning and mesoderm induction during embryonic development.
This review further discusses GDF1’s structure, signaling pathway, and function across different
species.

Human
Structure
GDF1 encodes a secreted ligand of the TGFβ superfamily of proteins. The GDF1 protein
is a 12-15kDa secreted protein. It is synthesized as a preproprotein that contains a 29 amino acid
signal peptide, a 224 amino acid propeptide, and a 119 amino acid mature peptide which is
released following proteolysis at a dibasic cleavage site (Lee, 1991). It is mainly found in the
brain of embryos and is absent from most normal adult tissue (Figure 1.6).

81

Figure 1.6. Tissue-specificity of GDF1 and CERS1 mRNA and protein. RNA-seq was performed
using tissue samples from healthy human individuals in order to determine tissue-specificity of all
protein-coding genes. GDF1 and CERS1 are both predominantly expressed at high levels in human and
murine brain and male tissues and are nearly absent in most other tissues. Image copied and modified
from The Human Protein Atlas.

Interestingly, GDF1 is located on a bicistronic gene on chromosome 19 which also
produces the ceramide synthase 1 (CERS1) protein from a non-overlapping reading frame
(Figure 1.7). CERS1 catalyzes the synthesis of C18 ceramide and is primarily expressed in the
brain and male tissues (Ginkel et al., 2012) (Figure 1.6). The polycistronic structure of mRNAs
is an important aspect of translational control in prokaryotes, in which genes belonging to the
same functional pathways are often packaged into operons, which are transcribed into a single
mRNA (Jacob and Monod, 1961; Kozak, 2005) (Figure 1.8). However, they are rare in
eukaryotes such as mouse and human. The clusters of co-expressed genes may be conserved by
natural selection (Singer et al., 2005). A mammalian bicistronic transcript of SNURF-SNRPN has
been found to encode two independent proteins in human and mouse, and a polycistronic cDNA
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that encodes two functional enzymes is found in tomato plant too (García-Ríos et al., 1997; Gray
et al., 1999). Therefore, CERS1 and GDF1 may have functional connections in evolution.

Figure 1.7. Genomic context of Homo sapiens chromosome 19 -NC_000019.10 and schematic
representations of human GDF1 and CERS1 mRNA transcript. Upper: The human GDF1 and CERS1
genes are both located on 19p13.11. They are transcribed to a single bicistronic mRNA. Lower: The
mRNA transcript of GDF1 and CERS1 has eight exons, with the first six encoding for CERS1 and the last
two encoding for GDF1. Each vertical green line in the figure represents one mRNA transcript isoform,
with green block representing the exon and grey arrow representing the translating direction, respectively.
Image copied and modified from NCBI Database.
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Figure 1.8. Monocistronic vs polycistronic transcription in eukaryotes. A cistron is an alternative
term for "gene”, which is a region of DNA that encodes function. An mRNA molecule is said to be
monocistronic when it contains the genetic information to translate only a single protein. This is the case
for most of the eukaryotic mRNAs. On the other hand, polycistronic mRNA carries several open reading
frames, each of which is translated into a polypeptide. These polypeptides usually have a related function,
and their coding sequence is grouped and regulated together in a regulatory region, containing
a promoter and an operator. Most of the mRNA found in bacteria and archaea is polycistronic, as is the
human mitochondrial genome.

84

Signaling pathway
The encoded preproprotein of GDF1 is proteolytically processed to generate each subunit
of the disulfide-linked homodimer. GDF1 potentiates NODAL activity by stabilizing a low
molecular weight fraction (Fuerer et al., 2014). The NODAL-GDF1 heterodimer can bind to the
serine/threonine kinase receptors ACVR2B and ACVR1B and the EGF-CFC coreceptor
CRYPTO on the cell surface. Activated ACVR1B recruits and phosphorylates SMAD2 or
SMAD3 in the cytoplasm. Two SMAD3 (or two SMAD2) then bind to SMAD4 and forms a
heterodimeric complex. This complex then enters the cell nucleus and binds directly to DNA
where it acts as a transcription factor for various genes (Sandomenico and Ruvo, 2019) (Figure
1.9).
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Figure 1.9. Schematic diagram of GDF1 signaling pathway. GDF1 and NODAL form a dimer which
binds to ACVR1B and ACVR1B as well as the coreceptor CRYPTO on the cell surface. The ligand
binding triggers the phosphorylation of the type I receptor by the type II kinase, as well as the
phosphorylation of SMAD2 (or SMAD3) on the inner surface of the cell membrane. Activated SMAD2/3
then forms a complex with Smad4 and translocate into the nucleus to affect the expression of various
target genes.
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Function
GDF1 is involved in the establishment of left-right asymmetry in early embryogenesis
and in neural development in later embryogenesis. During early embryonic development, GDF1
controls the formation of organizing centers that are necessary for normal forebrain and
branchial arch development in the anterior primitive streak (Olov Andersson et al. 2006). In the
axis patterning of the embryo, the node is the central initiator of left-right asymmetry (Figure
1.10). NODAL and GDF1 secreted from the ventral node define the left side of the embryo
through interactions with LEFTY2 and PITX in the lateral plate mesoderm. Meanwhile, a
leftward flow induced by active cilia prevents NODAL from signaling on the right side of the
embryo, in conjunction with the right side-specific expression of Cerberus (Quail et al., 2013).
Mutations in this gene are associated with several congenital cardiovascular malformations
(Marek- Yagel et al., 2020). For example, deletion of the GDF1 gene causes heterotaxy with
varied complex heart malformations of left–right patterning (Jin et al., 2017). In the adult, the
expression of GDF1 is almost exclusively restricted to the central nervous system. Recent studies
revealed that GDF1 has a protective role in pathological cardiac hypertrophy. Cardiac-specific
GDF1 overexpression markedly attenuated cardiac hypertrophy, fibrosis, and cardiac
dysfunction, whereas loss of GDF1 in cardiomyocytes exaggerated the pathological cardiac
hypertrophy and dysfunction in response to pressure overload (Zhang et al., 2014).
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Figure 1.10. Schematic outline of the NODAL/GDF1 signaling pathway during establishment of
left-right asymmetry. During gastrulation, the node is the central initiator of left-right asymmetry. GDF1
and NODAL from the node define the left side of the embryo through interactions with LEFTY2 and
PITX in the lateral plate mesoderm. Meanwhile, a cilia leftward flow and CERBERUS signal prevent
NODAL from signaling on the right side of the embryo.

Although GDF1 is absent from most normal adult tissue, its expression re-emerges
during cancer progression. It was found that GDF1 has a novel functional role in tumor
suppression. Abnormal promoter hypermethylation is the major mechanism causing the loss of
GDF1 in gastric cancer. Loss of GDF1 is associated with poor survival in stomach cancer
patients. GDF1 functions to stimulate p-SMAD2/3 and p21, but it inhibits p-Rb in human gastric
cells (Yang et al., 2016). Based on this notion, it is plausible that GDF1 may exert comparable
antitumor functions in other cancers, which warrants future investigation.

88

Mouse
Structure
Mature mouse and rat GDF1 shares an 81% sequence identity with human GDF1. The
mouse GDF1 gene is located on chromosome 8 upstream and in close proximity to the gene
coding for CERS1 with which it is expressed on the same bicistronic mRNA (Ginkel et al.,
2012). In the early embryonic stage, a 1.4kb mRNA fragment that expresses only GDF1 is
present. From embryonic day 9 and onwards, an additional 3kb fragment is detected which
consists of CERS1 and GDF1 in a bicistronic mRNA. In the adult mouse, only the 3kb fragment
is expressed; the 3-kb species is also found in adult spinal cord, cerebellum, and brain stem as
well as in fetal brains from various developmental stages (Lee, 1991) (Figure 1.11).
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Figure 1.11. Genomic context of Mus musculus chromosome 8 – NC_000074.7 and schematic
representations of mouse GDF1 and CERS1 mRNA transcripts. Upper: The Mus musculus CERS1
and GDF1 gene are both located on 8; 8 B3.3. GDF1 is translated from a monocistronic mRNA early in
development, and from a bicistronic mRNA in later stages that also encodes CERS1. Lower: The
bicistronic mRNA of GDF1 and CERS1 has eight exons, with the first six encoding for CERS1 and the
last two encoding for GDF1. The monocistronic mRNA of GDF1 has two exons. Each vertical green line
in the figure represents one mRNA transcript isoform, with green block representing the exon and grey
arrow representing the translating direction, respectively. Image copied and modified from NCBI
Database.

Function
Similar as in human, GDF1 in mouse is involved in the establishment of left-right
asymmetry in early embryogenesis and in neural development in later embryogenesis. At early
stages of mouse development, GDF1 is expressed initially throughout the embryo node and then
most prominently in the primitive node, ventral neural tube, and intermediate and lateral plate
mesoderm (Shen, 2007). It is crucial for mouse embryonic development, particularly the leftright patterning, by acting as an upstream regulator of multiple symmetry-associated genes such
as Lefty2, Nodal, and Pitx. Deletion of the GDF1 gene leads to embryonic lethality in mice
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(Rankin et al., 2000). In late-stage embryos and adult mice, it is exclusively expressed in the
nervous system such as the brain, spinal cord, and the peripheral nerves (Lee, 1991). The loss-offunction of GDF1 in mice exhibited a variety of defects with disturbance in the left-right axis
formation, including heterotaxy and heart defects such as abnormal atrium and ventricle (Rankin
et al., 2000; Tanaka et al., 2007). In addition, mice with cardiac-specific overexpression of the
GDF1 gene are resistant to cardiac remodeling via inhibition of MEK–ERK1/2 and SMAD
signaling, indicating that GDF1 alleviates pressure overload-induced cardiac hypertrophy and
dysfunction (Yang et al., 2016).

Other animals
GDF1 is highly conserved across species (Andersson et al., 2007; Lee, 1990). It is the
functional equivalent of Xenopus and chicken VG1, or zebrafish DVR1, or yeast Longevityassurance gene 1 (Lag1) (Table 1.6). GDF1 has been proposed to be a mammalian ortholog of
Xenopus, zebrafish, and chicken Vg1, due to their sequence similarity and the fact that both
GDF1 and Vg1 regulate left–right patterning (Helde and Grunwald, 1993; Joseph and Melton,
1998; Shah et al., 1997; Wall et al., 2000). It also requires Activin as receptors and EGF-CFC
proteins as coreceptors (Cheng et al., 2003). Hyl-1, a worm homolog to yeast LAG1, represents a
novel mechanism for affecting lifespan in C. elegans (Tedesco et al., 2008). GDF1 is the
mammalian homologue of yeast Lag1 which is differentially expressed during the yeast
replicative life span and was shown to play a role in determining yeast longevity (Wang et al.,
2007).
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Table 1.7. Homologs of GDF1 in different species
Species
Mammalian
Xenopus, Zebrafish, and chicken
C. elegans
Yeast

Homologs
GDF1
Vg1
Hyl-1
Lag1
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1.6. Rationale and Significance of Thesis Research

Rationale
Acute myeloid leukemia (AML) is a cancer of the myeloid lineage of blood cells. The
disease can progress quickly and be fatal within days or months if left untreated. Currently, there
are no viable curative treatments for AML besides bone marrow transplant, which has potentially
life-threatening side effects.

Significance
Chapters 2 and 3 explore the role of growth/differentiation factor 1 (GDF1) as a regulator
of ceramide metabolism, as well as its therapeutic efficacy in preclinical models of AML.
Experimental data indicates that GDF1 has the potential to promote ceramide buildup by
downregulating the expression of genes encoding for ceramide de-toxifying enzymes. In
addition, GDF1 was observed to regulate hematopoiesis, including specific regulation of
erythropoiesis, as well as exert combinatorial efficacy with cytarabine in vivo. These results
rationalize further investigation of GDF1 as a potential therapeutic modality for AML.
Chapter 4 evaluates the role of obesity in the progression of AML, where it facilitates a
ceramide-dependent pathway. That obesity directly accelerates the development of AML
emphasizes the necessity of elucidating mechanisms linking cancer and obesity to better address
and reduce the burden of both diseases.
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1.7. Aims and Hypotheses of Individual Chapters

CHAPTER 2
GDF1 REGULATES CERAMIDE DETOXIFICATION IN ACUTE MYELOID LEUKEMIA
Hypothesis - GDF1 regulates ceramide detoxification in acute myeloid leukemia (AML).
Aim 1 - To study GDF1 regulation of ceramide metabolism in AML.
Aim 2 - To evaluate SMAD2/3 and STAT3 signaling as GDF1-mediated pathways in AML.

CHAPTER 3
REGULATION OF HEMATOPOIESIS BY GDF1 IN ACUTE MYELOID LEUKEMIA
Hypothesis - GDF1 promotes hematopoiesis in AML.
Aim 1 - To investigate GDF1 regulation of hematopoiesis and erythropoiesis.
Aim 2 - To evaluate the anti-AML therapeutic efficacy of GDF1 alone or in combination with
cytarabine.

CHAPTER 4
OBESITY PROMOTES ACUTE MYELOID LEUKEMIA PROGRESSION BY
UPREGULATING THE CERAMIDE-MEDIATED NADPH OXIDASE 2
Hypothesis - Obesity promotes AML progression by upregulating the ceramide-mediated
NADPH oxidase 2.
Aim 1 - To demonstrate that obesity mediates the progression of AML.
Aim 2 - To show that obesity in AML upregulates the ceramide-medicated NADPH oxidase 2.
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CHAPTER 2

GDF1 REGULATES CERAMIDE DETOXIFICATION IN ACUTE MYELOID LEUKEMIA4

2.1. Abstract
Growth/differentiation factor 1 (GDF1) is primarily known for its role in development,
especially that of the heart. GDF1 is a member of the transforming growth factor beta (TGFβ)
superfamily. The gene encoding for GDF1 is encoded from a rare bicistronic transcript that also
encodes for ceramide synthase 1 (CERS1). Due to its connection to CERS1, it was speculated
that GDF1 may play a role in sphingolipid metabolism or signaling. Therefore, the regulation of
CERS1/GDF1 was investigated in acute myeloid leukemia (AML) in addition to its effects on the
expression of sphingolipid-modifying enzymes. In this study, it is reported for the first time that
GDF1 can alter sphingolipid metabolism in a manner that may restore AML sensitivity to
nanoliposomal C6-ceramide (Lip-C6). Gene expression analysis revealed that CERS1/GDF1 is
variably expressed in AML. Treatment of leukemia cells with recombinant GDF1 reduced the
expression of ceramide-neutralizing enzymes encoded by UDP-glucose ceramide
glycosyltransferase (UGCG) and sphingomyelin synthase 1 (SGMS1). It was further shown that
GDF1 exerted divergent transforming growth factor beta receptor 1 (TGFβR1)-dependent
upregulation of SMAD2/3 and downregulation of STAT3. Altogether, these results identify
GDF1 as a novel regulator of ceramide metabolism in AML. Moreover, this study suggests that
GDF1 may be able to restore anti-AML therapeutic efficacy of therapeutics such as Lip-C6.

4

Weiyuan Wang, Paul T. Toran, Andrea L. Cote, Emma J. Arsenault, Alexander J. Thorpe, Vasiliki Papakotsi,
Emily C. Sullivan, Rachel J. Sabol, Mary A. Hurley, Brian M. Barth. GDF1 Regulates Ceramide Detoxification in
Acute Myeloid Leukemia. In preparation for submission.

95

2.2. Introduction
Acute myeloid leukemia (AML) is a heterogenous malignancy characterized by the
expansion of immature myeloid progenitors, primarily in the blood and bone marrow (Grimwade
et al., 2016). Genetic abnormalities and molecular abnormalities such as chromosomal changes
are common in AML (Kumar, 2011). This cancer can occur in several different ways. AML that
arises from myelodysplastic syndrome (MDS) is known as AML with MDS-related changes
(AML-MRC) (Arber et al., 2016; Papaemmanuil et al., 2016). Other patients that do not have
clinical history of prior MDS are classified as de novo AML (DN-AML). In general, AML-MRC
occurs in older patients and has more unfavorable outcomes (Arber and Erba, 2020). The poor
prognostics and increasing incidence of this disease demand novel therapies for the treatment of
AML (Baldus et al., 2007). One potential therapy of particular interest is ceramide, a
proapoptotic sphingolipid which, when formulated into a nanoliposome, becomes a potent
anticancer drug called nanoliposomal C6-ceramide (Lip-C6) (Barth et al., 2011). The AMLMRC variant of AML appears to be predominantly sensitive to Lip-C6 due whereas enhanced
ceramide metabolism in DN-AML predominates as a mechanism of resistance (Barth et al.,
2019). For this reason, increasing sensitivity to ceramide-regulating therapeutics is an adequate
strategy to combat drug resistance in cancer.
Growth/differentiation factor 1 (GDF1) is a member of the transforming growth factor
beta (TGFβ) superfamily. It is primarily known for its role in development and stem cell biology,
including anterior axis development, left-right patterning, and cardiac development (Andersson
et al., 2006; Karkera et al., 2007a). GDF1 is a ligand of the transforming growth factor beta
receptor 1 (TGFβR1), a receptor serine/threonine kinase which functions through receptor
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heterodimerization and activation of downstream SMAD signaling (Moore-Smith and Pasche,
2011).
GDF1 is also a factor in AML, wherein it regulates sphingolipid metabolism through
downregulation of genes that produce enzymes to break down ceramide (Wang et al., 2019). The
gene encoding for GDF1 is a rare bicistronic gene that also encodes for ceramide synthase 1
(CERS1). Both genes are under control of the same promoter, which is found upstream of
CERS1 (Meyers-Needham et al., 2012). CERS1 promotes the formation of C18:0
dihydroceramide from dihydrosphingosine, as well as C18:0 ceramide from sphingosine in
salvage ceramide biosynthetic pathways (Mullen et al., 2012).
The present study explores a hypothesis that GDF1 regulates ceramide detoxification in
AML, which would enhance the sensitivity of AML to ceramide-regulating therapies such as
Lip-C6. This study first demonstrates that the CERS1/GDF1 transcript is variably expressed in
AML, with a slight upregulation in AML-MRC. Furthermore, treatment with recombinant GDF1
was shown to reduce the expression of enzymes that break down ceramide, while also
upregulating SMAD2/3 phosphorylation and downregulating STAT3 phosphorylation in a
TGFβR1-dependent manner.

2.3. Results
The efficacy of Lip-C6 was first evaluated in murine models of AML. Both DN-AML
(FLT3ITD and MLL-AF9) and AML-MRC (Nup98-HoxD13) models were used. Lip-C6 therapy
was more effective in reducing the colony forming ability of bone marrow from AML-MRC
mouse models as compared with bone marrow from DN-AML or wildtype mouse models (Barth
et al., 2019) (Figure 2.1A). Similarly, in vivo treatment with Lip-C6, but not the nanoliposomal
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ghost control (Lip-Ghost), significantly decreased CD11b+/Gr-1+ myeloid leukemia cells in
AML-MRC mice but not DN-AML mice (Barth et al., 2019) (Figure 2.1B).

Figure 2.1. AML-MRC is more sensitive to Lip-C6 compared with DN-AML. (A) Bone marrow of
DN-AML (FLT3ITD and MLL-AF9) and AML-MRC (Nup98-HoxD13) mice was harvested and treated
with varying concentrations of ceramide nanoliposome (Lip-C6) in a colony-forming assay. (*p<0.05,
ANOVA) (B) DN-AML (FLT3ITD) and AML-MRC (Nup98-HoxD13) transgenic mice models were
treated daily for 10 days with Lip-C6 (11.6 mg/kg) or Lip-Ghost, which is a nanoliposome without
ceramide. Mice were euthanized, and bone marrow was collected, prepared, and analyzed via flow
cytometry to evaluate Gr-1+CD11b+ cells, representing leukemia burden. *P = .045 (n = 4 per group;
unpaired Student t test with Welch’s correction) comparing leukemia burden in AML-MRC mice treated
with Lip-C6 versus Lip-Ghost. Lip-C6: Nanoliposomal C6-ceramide, Lip-Ghost: Nanoliposomal Ghost.
Adapted from published manuscript (Barth et al., 2019).
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A role for GDF1 was next evaluated as a possible explanation for the observed
differences in sensitivity to Lip-C6 between AML-MRC and DN-AML. It was speculated that
GDF1 may increase the sensitivity to ceramide-based therapies in AML by impacting ceramide
metabolism. CERS1/GDF1 expression was initially evaluated by analyzing RNA sequencing
data from the BEAT AML dataset (Tyner et al., 2018). Patient samples (n=404) from the BEAT
AML dataset have varying expression of CERS1/GDF1 (Figure 2.2A) (Tyner et al., 2018).
CERS1/GDF1 is also variably expressed in the bone marrow of murine transgenic mouse models
of AML and other myeloid hematologic disorders, with the data trend mirroring that of the
BEAT AML patient data (Figure 2.2B). More specific comparison of bone marrow from AMLMRC and DN-AML mouse models indicated that GDF1 is expressed at different levels in these
two variants of AML. Despite a high amount of variability, GDF1 expression was generally
observed to be greater in AML-MRC when compared to DN-AML (Figure 2.2C). Therefore,
these differences in CERS1/GDF1 expression may be responsible for distinct sensitivity to LipC6 between AML-MRC and DN-AML.
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Figure 2.2. CERS1/GDF1 is differentially expressed in AML. (A) RNA sequencing data from AML
patients (n=404) in the BEAT AML dataset was analyzed for expression of CERS1/GDF1 and found to
be mostly downregulated (samples with matched transcriptomic and genomic sequencing) (Tyner et al.,
2018). (B, C) Bone marrow samples from various transgenic mouse models of both DN-AML (FLT3ITD
and MLL-AF9) and AML-MRC (Mx1-Asxl1+/-; Mx1-Srsf2P95H; Mx1-Tet2+/-; Mx1-Asxl1+/-Tet2+/-;
Nup98-HoxD13; Vav1-Tert+/-) (n=22) were analyzed via RT-qPCR. Wildtype and leukemic murine
tissue samples were age- and sex- matched and housekeeping gene normalization was performed. Not all
subtypes cluster, indicating that distinct molecular evolution of the disease may contribute to differential
regulation of CERS1/GDF1.

Leukemia where CERS1/GDF1 is downregulated may benefit from treatment with
recombinant GDF1 to gain a possible therapeutic effect. CERS1/GDF1 was observed to be
downregulated in the bone marrow of FLT3ITD transgenic mice, a model of DN-AML (Figure
2.3A). In contrast, the expression of UGCG and SGMS1 was augmented in the bone marrow of
these DN-AML mice (Figure 2.3A). Interestingly, in vivo treatment with the hypomethylating
agent decitabine augmented CERS1/GDF1 expression while downregulating UGCG and SGMS1
expression (Figure 2.3A). These results indicate an inverse correlation between CERS1/GDF1
and UGCG and SGMS1 expression in DN-AML. The ability of recombinant GDF1 to regulate
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the expression of UGCG and SGMS1, genes encoding enzymes responsible for ceramide
neutralization, was further evaluated by in vitro treatment of AML cell lines. Recombinant
GDF1 treatment of HL-60, Kasumi-1, and Kasumi-3 cells led to a downregulation of expression
for both UGCG and SGMS1 (Figure 2.3B).
Phosflow was used to further evaluate GDF1-mediated signaling in AML cell lines.
Recombinant GDF1 treatment increased phosphorylation of SMAD2/3 while simultaneously
decreasing tyrosine phosphorylation of STAT3 (Figure 2.3C-D). The TGFβR1 inhibitor IN-1130
blocked GDF1-stimulated SMAD2/3 phosphorylation while also preventing the GDF1-mediated
decrease in tyrosine phosphorylation of STAT3 (Figure 2.3C-D). This demonstrated a TGFβR1dependent mechanism for GDF1 in AML cells. In contrast, TGFβ and growth/differentiation
factor 3 (GDF3), which are related to GDF1 and can also engage TGFβR1, did not fully
recapitulate the effects of GDF1 on SMAD2/3 and STAT3 signaling. Specifically, TGFβ
similarly increased SMAD2/3 phosphorylation but did not impact STAT3 tyrosine
phosphorylation (Figure 2.3C-D). More so, GDF3 similarly downregulated STAT3 tyrosine
phosphorylation but had no effect on SMAD2/3 phosphorylation (Figure 2.3C-D). This is despite
GDF1 and GDF3 having recently been suggested to be evolutionarily linked and shown to have
partially redundant functions in the pre-gastrulation embryo (Opazo and Zavala, 2018). The
unique ability of GDF1 to both increase SMAD2/3 phosphorylation and decrease STAT3
tyrosine phosphorylation may be due to the engagement of a separate co-receptor from other
related ligands in addition to its TGFβR1 engagement. Overall, these results suggest that GDF1
may have a unique impact on leukemia cells compared to other ligands of the TGFβR1 system.
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Figure 2.3. Treatment with recombinant GDF1 triggers multiple cellular effects. (A) FLT3ITD mice
were treated with the hypomethylating agent decitabine. Bone marrow samples were obtained and RTqPCR was used to analyze the expression change of genes encoding for ceramide neutralizing enzymes.
Decitabine treatment led to an increased expression of CERS1/GDF1 and a decreased expression of
UGCG and SGMS1 (B) Recombinant GDF1 was administered in vitro to three leukemia cell lines: HL60, Kasumi-1, and Kasumi-3 (200 ug/ml, 48 hours). RT-qPCR was performed to analyze the expression
of UGCG and SGMS1. Both UGCG and SGMS1 were downregulated following treatment. (C, D)
Kasumi-1 cells were treated with the TGFβR1 inhibitor IN-1130, recombinant GDF1, a combination of
recombinant GDF1 and IN-1130, TGFβ, or GDF3. Phosflow was used to evaluate phosphorylation of
SMAD2/3 and tyrosine phosphorylation of STAT3 (residue Y705). In a TGFβR1-dependent fashion,
GDF1 both (C) upregulated SMAD2/3 signaling and (D) downregulated STAT3 signaling. * p > 0.05,
n=3.
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2.4. Discussion
These findings highlight a role for GDF1 as a regulator of ceramide metabolism in AML.
AML-MRC is uniquely sensitive to Lip-C6 as compared with DN-AML (Barth et al., 2019),
which further highlights the need to increase DN-AML sensitivity to ceramide-based
therapeutics. It was observed that the expression of CERS1/GDF1 is highly variable in both
AML patient samples and murine models of AML. Interestingly, GDF1 expression was
generally lower in the bone marrow of DN-AML transgenic mouse models as compared with
AML-MRC transgenic mouse models. These discrepancy in GDF1 expression may help explain
differential sensitivity to Lip-C6 in AML. Increasing GDF1 expression or administering
recombinant GDF1 may enhance AML sensitivity to Lip-C6 and other ceramide-elevating
therapeutics.
Ceramide is a powerful proapoptotic sphingolipid with the potential to treat many
different cancers (Barth et al., 2011). Unfortunately, AML can resist Lip-C6 by upregulating
ceramide-neutralizing enzymes (Barth et al., 2019). Therefore, strategies to inhibit these
enzymes, or to downregulate their expression, are of interest in the treatment of AML and other
ceramide-resistant cancers. Recombinant GDF1 was observed to lower the expression of
ceramide-neutralizing enzymes encoded by UGCG and SGMS1. These enzymes prevent
apoptosis by neutralizing proapoptotic ceramide to nonapoptotic sphingolipid metabolites.
This study further indicated that GDF1 promoted the phosphorylation of SMAD2/3,
while simultaneously inactivating STAT3 by decreasing its tyrosine phosphorylation. Both these
effects occurred in a TGFβR1-dependent fashion and distinct from the single SMAD2/3regulating or STAT3-regulating effects of the related ligands TGFβ and GDF3, respectively.
This suggests that GDF1 has a unique capacity to regulate leukemia cells in by engaging
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TGFβR1 to regulate both SMAD2/3 and STAT3 capability to shift sphingolipid metabolism
towards ceramide accumulation by downregulating the expression of genes encoding for
ceramide detoxification enzymes (Figure 2.4).

Figure 2.4. Schematic diagram of GDF1 signaling pathway. GDF1, translated from a bicistronic gene,
signals through a receptor serine/threonine kinase system that includes TGFβR1. Upon ligand binding, the
receptor system triggers phosphorylation of SMAD2/3, which induces the expression of target genes.
Simultaneously, the receptor system inactivates STAT3 by decreasing its tyrosine phosphorylation.
Collectively, the effects of GDF1 is to block ceramide neutralization to glucosylceramide by binding to
the promoter region of genes such as UGCG, which encodes for GCS. In this way, GDF1 can help to
increase intracellular ceramide levels. CERS1, ceramide synthase 1; GCS, glucosylceramide synthase;
UGCG, gene encoding for GCS.
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2.5. Materials and Methods
BEAT AML dataset
The BEAT AML program is a collaborative program for functional genomic data
integration involving numerous academic medical centers working collectively to accrue and
characterize a large cohort of AML patient specimens. Information available in the BEAT AML
dataset includes whole exome sequencing and RNA-sequencing, which is available through
recent publication (Tyner et al., 2018). For the present study, samples from the BEAT AML
dataset that have paired genomic and transcriptomic data were analyzed.

Cell culture
The human Kasumi-1 and Kasumi-3 cell lines were maintained in RPMI-1640
supplemented with 20% FBS. Similarly, the human HL-60 cell line was maintained in Isocove’s
Modified Dulbecco’s Medium supplemented with 20% FBS. All cultures were incubated at 37°C
and 5% CO2.

Animal studies
C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla/J (Nup98-HoxD13), B6.Cg-Tg(Mx1cre)1Cgn/J-Asxl1tm1.1Iaai/J (+/-)(Mx1-Asxl1+/-), B6.Cg-Tg(Mx1-cre)1Cgn/J-B6J.B6NTac(SJL)Srsf2tm1.1Oaw/J (+/-)(Mx1-Srsf2P95H), B6.Cg-Tg(Mx1-cre)1Cgn/J-B6J.B6NTac(SJL)-B6;129STet2tm1.1Iaai/J(+/-)(Mx1-Tet2+/-), B6.Cg-Tg(Mx1-cre)1Cgn/J-B6J.B6NTac(SJL)-Asxl1tm1.1Iaai/JB6;129S-Tet2tm1.1Iaai/J(+/-)(Mx1- Asxl1+/-Tet2+/-), B6.Cg-Commd10Tg(Vav1-icre)A2Kio/J-B6.129STerttm1Yjc/J (+/-)(Vav1-Tert+/-) transgenic mice are commonly used murine models of MDS and
other myeloid hematologic disorders, many which evolve to AML-MRC (Chou et al., 2010; Hou
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et al., 2016; Kirwan et al., 2009; Nibourel et al., 2010; Slape et al., 2008). In contrast, B6.129Flt3tm1Dgg/J (Flt3ITD) and Kmt2atm2(MLLT3)Thr/KsyJ (MLL-AF9) transgenic mice were used as
models of DN-AML (Chen et al., 2019; Loghavi et al., 2014).
Bone marrow cells were isolated from the femurs and tibias of 4–8-month-old (male and
female) transgenic mice and their respective wildtype littermates for colony-forming assay, flow
cytometry, and RT-qPCR analysis. These transgenic mice include AML-MRC mouse models
such as Nup98-HoxD13, Mx1-Asxl1+/-, Mx1-Srsf2P95H, Mx1-Tet2+/-, Mx1-Asxl1+/-Tet2+/-,
Vav1-Tert+/-, as well as DN-AML mouse models such as MLL-AF9 and FLT3ITD. Mice were
submitted to the New Hampshire Veterinary Diagnostic Laboratory (NHVDL) at the University
of New Hampshire for histopathological evaluation. Leukemia was confirmed by the
investigative team and the NHVDL in transgenic mice based on spleen or bone marrow
histopathology, and/or peripheral blood smear evaluation. All animal studies were approved by
the Institutional Animal Care and Use Committee of the University of New Hampshire.

Ceramide Nanoliposome (Lip-C6) formulation and treatment
Lip-C6 and Lip-Ghost were generously prepared and provided by Dr. Mark Kester of the
University of Virginia. Briefly, lipids dissolved in chloroform, were combined in specific molar
ratios, dried to a film under nitrogen, and then hydrated by addition of 0.9% NaCl. Solutions
were sealed, heated at 60°C for 60 minutes, subjected to vortex mixing, and sonicated until light
no longer diffracted through the suspensions. Lipid vesicle-containing solutions were then
extruded at 60°C by passing the solutions 10 times through 100 nm polycarbonate filters using
an Avanti Mini-Extruder (Avanti Polar Lipids, Alabaster, AL). Size and charge were validated
using a Malvern Zetasizer Nano ZS at 25°C, and C6-ceramide encapsulation into anionic
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formulations was quantified by mass spectroscopy. Liposomal suspensions were stored at room
temperature until use.
Therapeutic efficacy of Lip-C6 as a standalone treatment was evaluated using transgenic
mouse models. 4–8-month-old (male and female) AML-MRC (Nup98-HoxD13) and DN-AML
(Flt3ITD) transgenic mice were injected with Lip-C6 (11.6 mg/kg) or Lip-Ghost (volume
matched) daily for 10 days. One day after the final injection, mice were euthanized and bone
marrow was collected from femurs and tibias, spleens were removed and measured, and blood
was collected by cardiac puncture for blood smears.

Recombinant GDF1 formulation and treatment
Recombinant human GDF1 was purchased from R&D Systems. It arrived in a lyophilized
form with BSA as a carrier protein and was re-suspended according to the manufacture’s
direction. Therapeutic efficacy of recombinant GDF1 as a standalone treatment was evaluated
using HL-60, Kasumi-1, and Kasumi-3 cell lines. These cell lines were first cultured in T25
flasks, then 1.2 x 106 cells were seeded into each well of a six-well plate and treated with
recombinant GDF1 reagent (200 ug/ml, 48 hours).

Colony-forming assays
Murine bone marrow mononuclear cells were isolated and prepared from transgenic mice
and their wildtype counterparts and cleaned of debris using Ficoll-Paque PLUS (GE Healthcare
Life Sciences) density gradient centrifugation. Prior to colony-forming assays, leukemia was
confirmed by the investigative team and the NHVDL in transgenic mice based on spleen or bone
marrow histopathology, and/or peripheral blood smear evaluation. Murine samples were cultured
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in triplicate in 12-well plates at a density of 2.5 x 104 cells per well in Murine MethoCult GF
(#M3434) (StemCell Technologies, Vancouver, BC). The plating density was selected to yield
typical wildtype or transgenic mouse colony out-growth of ~30-150 colonies per well in the
absence of drug treatment. Sterile water was added into empty wells, and space between wells, to
maintain optimal humidity necessary for colony growth. During assay set-up, murine bone
marrow cells were added simultaneously to the culture media with Lip-C6 or controls. The
cultures were mixed vigorously and then dispensed to multi-well plates and incubated for 10-14
days. Blinded investigators manually counted total colonies, including blast or miscellaneous
colonies.

RT-qPCR analysis
Total cellular RNA from mouse bone marrow samples or cell lines was extracted and
cleaned using Zymo Research kits. RNA quality was evaluated using a NanoDrop 8000
spectrophotometer (Thermo Fisher Scientific), and reverse transcribed with Taq polymerase to
generate cDNA. Quantitative polymerase chain reaction (qPCR) was performed using
PrimeTime® Gene Expression Master Mix (Integrated DNA Technologies) on a CFX96 RealTime PCR System (Biorad). Gene expression was determined using the 2–DDCt method using
cycle threshold (Ct) values for target genes as well as two endogenous reference genes (ACTB
and TBP). Primer and probe assays were obtained from Integrated DNA Technologies.

Flow cytometry and Phosflow
Isolated bone marrow cells from transgenic mice were prepared and stained with Mouse
Fc Block, fluorophore-conjugated anti-mouse Gr-1 (clone RB6-8C5) and fluorophore-conjugated
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anti-mouse CD11b (clone M1/70) monoclonal antibodies from BD Biosciences (San Jose, CA).
Gr-1+ CD11b+ cells were evaluated and quantified as representative of leukemia burden.
Phosflow was performed to evaluate phosphorylation of SMAD2/3 on serine/threonine residues
and tyrosine phosphorylation of STAT3 (residue Y705). For Phosflow studies, Kasumi-1 cells
were fixed, permeabilized, and stained with specific fluorophore-conjugated antibodies, all with
reagents from BD Biosciences. Flow cytometry was performed at the University of New
Hampshire’s University Instrumentation Center using a Sony SH800Z sorting flow cytometer.

Statistical analysis
GraphPad Prism (GraphPad Software, La Jolla, CA) was used to perform data analyses.
For dose-response colony-forming assays, a 2-way ANOVA with a Tukey’s post hoc multiple
comparisons test was performed. Comparisons of colony-forming, RT-qPCR, or Phosflow data
were made using a student t-test or 1-way ANOVA followed by a Tukey’s multiple comparisons
test.
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CHAPTER 3

REGULATION OF HEMATOPOIESIS BY GDF1 IN ACUTE MYELOID LEUKEMIA5

3.1. Abstract
In acute myeloid leukemia (AML), hematopoiesis is altered such that maturation arrests
at the myeloid blast phase, leading to the expansion and proliferation of myeloid progenitors.
Consequently, restoration of normal hematopoiesis may be a viable strategy to treat AML and
other related blood disorders. Growth/differentiation factor 1 (GDF1) is a transforming growth
factor beta (TGFβ) superfamily member protein. This ligand, which is an important factor in
embryonic development, may also be effective in re-establishment of normal hematopoiesis in
AML. Earlier GDF1 was identified as a potential treatment to enhance sensitivity to ceramidebased therapeutics, due to a role downregulating ceramide-neutralizing enzymes. In the present
study, therapeutic efficacy is reported for recombinant GDF1 as a standalone agent as well as in
combination with cytarabine (AraC). It was determined that recombinant GDF1 treatment
promotes blood cell differentiation in cells exhibiting abnormal hematopoiesis, while not
impacting normal hematopoiesis. More interestingly, recombinant GDF1 demonstrated an ability
to promote erythropoiesis. Collectively, these studies highlight the potential efficacy of
recombinant GDF1 as a hematopoietic-regulating anti-AML therapy.

5

Weiyuan Wang, Paul T. Toran, Alexander J. Thorpe, Emma J. Arsenault, Andrea L. Cote, Emily C. Sullivan,
Vasiliki Papakotsi, Brian M. Barth. Regulation of Hematopoiesis by GDF1 in Acute Myeloid Leukemia. In
preparation for submission.
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3.2. Introduction
Acute myeloid leukemia (AML) is characterized by expansion of immature myeloid cells
within the peripheral blood and bone marrow (Grimwade et al., 2016). In AML and related
myeloid hematologic malignancies, such as myelodysplastic syndrome (MDS), the
differentiation of the myeloid lineage is arrested so that there is an accumulation of blasts
expressing markers for monocytes, erythroid cells, and megakaryocytes (Saultz and Garzon,
2016). AML can be classified as either AML with MDS-related changes (AML-MRC) or as de
novo AML (DN-AML) if there is no prior history of MDS or MDS-related changes (Arber and
Erba, 2020; Barth et al., 2019).
The transforming growth factor-beta (TGFβ) superfamily member growth/differentiation
factor 1 (GDF1) has a profound role in embryonic development and stem cell biology. In
particular, it is involved in body plan and cardiac development (Andersson et al., 2006; Karkera
et al., 2007b). GDF1 can bind to TGFβR1, which is a receptor serine/threonine kinase (MooreSmith and Pasche, 2011). The gene encoding for GDF1 is a rare bicistronic gene that also
encodes for ceramide synthase 1 (CERS1). Both genes are under control of the same promoter,
which is found upstream of CERS1 (Meyers-Needham et al., 2012). CERS1 promotes the
formation of C18:0 dihydroceramide from dihydrosphingosine, as well as C18:0 ceramide from
sphingosine in salvage ceramide biosynthetic pathways (Mullen et al., 2012).
Ceramide-based therapeutics are under investigation for the treatment of AML and other
cancers due to their apoptosis-promoting abilities (Barth et al., 2011). In particular,
nanoliposomal C6-ceramide (Lip-C6) has shown efficacy in AML-MRC but not DN-AML, due
to enhanced metabolism of ceramide in DN-AML (Barth et al., 2019). Recently, recombinant
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GDF1 was shown to downregulate ceramide metabolism and signal in a TGFβR1-dependent
fashion in AML cells (Wang et al., 2019).
In the present study, anti-AML therapeutic efficacy of recombinant GDF1 was more
closely evaluated by focusing on its regulation of hematopoiesis. It was found that recombinant
GDF1 alters malignant hematopoiesis by promoting differentiation, as well as by specifically
promoting erythropoiesis (red blood cell development). Interestingly, recombinant GDF1 did not
appear to have an impact on normal blood cell differentiation. Additionally, recombinant GDF1
treatment exerted therapeutic efficacy in combination with the standard of care drug cytarabine
(AraC). Taken together, this study provides evidence for the use of recombinant GDF1 as a
potential therapy for AML due to its unique ability to regulate malignant hematopoiesis.

3.3. Results
The physiological impact of recombinant GDF1 was first assessed using bone marrow
from transgenic mouse models of AML. When bone marrow from DN-AML transgenic mice
was treated with recombinant GDF1 in vitro, blood cell differentiation was improved. This was
evident by an increase in CFU-M, BFU-E, and CFU-E and reduction in CFU-GM. Recombinant
GDF1 treatment effectively promoted differentiation while decreasing the number of immature
cells in this model (Figure 3.1). Notably, these results also demonstrated that recombinant GDF1
promoted erythropoiesis (red blood cell development). Importantly, recombinant GDF1
treatment did not significantly affect blood cell differentiation of bone marrow from wildtype
mice (Figure 3.1). Therefore, recombinant GDF1 appears to only affect abnormal, malignant
hematopoiesis, while not impacting normal hematopoiesis.
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Figure 3.1. GDF1 treatment promotes hematopoiesis in leukemic mice alone. Bone marrow from
FLT3ITD transgenic and C57BL/6J wildtype mice were treated with recombinant GDF1 in colony forming
assays for 10 days. GDF1 caused a decrease in CFU-GM (immature myeloid cells) and an increase in
maturation of monocytes (CFU-M) and erythrocytes (BFU-E and CFU-E) from FLT3ITD mice but not
wildtype mice, suggesting GDF1 only impacts abnormal hematopoiesis (*p<0.05, 1-way ANOVA).

Next, the Nup98-HoxD13 transgenic mouse model of AML-MRC was treated with
recombinant GDF1, as well as with Lip-C6 and its control nanoliposomal Ghost (Lip-Ghost).
Flow cytometry of harvested bone marrow revelaed that recombinant GDF1 promoted
erythropoiesis, as evident by the increase in erythroid progenitors to a similar degree of that
triggered by Lip-C6 (Figure 3.2). This treatment also reduced the amount of immature myeloid
cells (myeloid leukemia cells), again in a similar effect of that of Lip-C6, suggesting that
recombinant GDF1 also regulates myelopoiesis in AML-MRC (Figure 3.2).
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Figure 3.2. GDF1 regulates hematopoiesis in mice with AML-MRC. Nup98-HoxD13 transgenic mice
were injected with recombinant GDF1, Lip-C6, or Lip-Ghost for 10 days. Following treatment, mice were
euthanized, and bone marrow erythroid progenitors (A, C) and immature myeloid cells (B, D) were
assessed using flow cytometry. Erythroid progenitors were upregulated while immature myeloid cells
(myeloid leukemia blasts) were downregulated by GDF1 or Lip-C6 treatment (*p<0.05, 1-way ANOVA).

The effects of recombinant GDF1 treatment on the survival of mice engrafted with
C1498 AML cells was also assessed. Overall survival was not significantly impacted by
treatment with recombinant GDF1 or the standard of care agent AraC alone. However,
combinatorial treatment with recombinant GDF1 and AraC significantly extended overall
survival in this highly aggressive DN-AML model (Figure 3.3). These results suggest that
recombinant GDF1 may be an effective agent to be combined with standard of care anti-AML
chemotherapy, which can elevated endogenous ceramide levels, as well as other ceramide-based
therapeutics.
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Figure 3.3. GDF1 improves the survival rate of mice engrafted with AML and has a combinatorial
effect with AraC. C57BL/6J wildtype mice were engrafted with C1498 AML cells, and then treated with
recombinant GDF1 +/- AraC. Logrank analysis was used to evaluate survival. AraC: cytarabine.

3.4. Discussion
These findings substantiate recombinant GDF1 as a potential treatment for AML. Current
therapies for AML include drugs such as AraC, as well as novel therapies under development,
such as Lip-C6 (Barth et al., 2019; Galmarini et al., 2002). Unfortunately, AML often develops
resistance to these therapies. For that reason, the development of strategies to combat resistance
is a pressing challenge. Previously, GDF1 was shown to regulate sphingolipid metabolism by
downregulating genes associated with ceramide neutralization (Wang et al., 2019). In addition, it
was previously shown that GDF1 signaled uniquely by stimulating SMAD2/3 phosphorylation
while downregulating STAT3 tyrosine phosphorylation in a TGFβR1-dependent manner (Wang
et al., 2019). The present study further demonstrates, for the first time, that recombinant GDF1
can impact malignant hematopoiesis by promoting differentiation along the myeloid and
erythroid lineages. This may be beneficial as recombinant GDF1 only impacted malignant
hematopoiesis and not that from normal controls, highlighting the reduced possibility of offtarget effects. However, it is important to note that the present study focused solely on
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hematopoiesis in the bone marrow, and so its impacts on hematopoiesis in other tissues remains
in question. For instance, another group has found that a GDF15, another member of the TGFβ
superfamily, regulates stress erythropoiesis in the spleen (Hao et al., 2019). Therefore, future
research may focus on the hematopoietic-regulatory role of GDF1 in other tissues.
The promotion of erythropoiesis (red blood cell development) by GDF1 could have
further applications beyond AML. In low-risk MDS, incomplete erythropoiesis leads to
macrocytic anemia (Sibon et al., 2019). Other forms of anemia with red blood cell deficiency
including congenital hyperplastic anemia, also known as Diamond-Blackfan anemia as well as
anemia occurring with chronic illnesses such as infection and inflammatory disorders are also
triggered by failed differentiation of erythroid progenitors (Lipton et al., 1986; Means and
Krantz, 1992). It is possible, then, that the promotion of erythropoiesis by recombinant GDF1
may be useful in the treatment of anemia in a variety of other conditions.
These results further showed that recombinant GDF1 exerted combinatorial anti-AML
efficacy with AraC. In addition to acting as a nucleoside analog to promote DNA damage, AraC
also promotes the generation of endogenous ceramide (Galmarini et al., 2002; Saddoughi et al.,
2008). Therefore, these two treatments may work together by AraC triggering ceramide
production and recombinant GDF1 preventing the breakdown of ceramide. Recombinant GDF1
and AraC combined to significantly extend leukemic mouse survival, whereas single-agent
treatments had no beneficial effect on lifespan. Strikingly, this was a significant increase in
lifespan using a highly aggressive murine model of DN-AML.
In summary, this study demonstrated that recombinant GDF1 is a powerful regulator of
leukemic (abnormal) mouse hematopoiesis that does not affect wildtype (normal) mouse
hematopoiesis. This is an exciting finding, as it demonstrates that recombinant GDF1 may be
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unlikely to trigger side effects impacting normal, noncancerous hematopoiesis and
erythropoiesis. Increased survival due to combinatorial treatment with recombinant GDF1 and
AraC further indicates that recombinant GDF1 may be a suitable treatment to combine with
ceramide-based therapeutics. Future work may focus on the use of recombinant GDF1 in other
models of AML, as well as the combination of recombinant GDF1 with Lip-C6 or other
ceramide-based therapeutics.

3.5. Materials and Methods
Cell culture
Murine C1498 cells were maintained in RPMI-1640 supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin/streptomycin. All cultures were incubated at 37°C and 5% CO2.

Animal studies
C57BL/6-Tg(Vav1-NUP98/HOXD13)G2Apla/J (Nup98-HoxD13) transgenic mice are a
murine model of MDS, which fully recapitulates the cellular features of MDS and predictably
evolves to AML-MRC (Slape et al., 2008). In contrast, B6.129-Flt3tm1Dgg/J (Flt3ITD) transgenic
mice were used as models of DN-AML (Loghavi et al., 2014). Alternatively, wildtype C57BL/6J
mice were engrafted with 1 x 106 C1498 AML cells for combinatorial therapeutic studies.
Bone marrow cells were isolated from the femurs and tibias of 4–8-month-old (male and
female) transgenic mice and their respective wildtype littermates for colony-forming assay or
flow cytometry analysis. Mice were submitted to the New Hampshire Veterinary Diagnostic
Laboratory (NHVDL) at the University of New Hampshire for histopathological evaluation.
Leukemia was confirmed by the investigative team and the NHVDL in transgenic mice based on
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spleen or bone marrow histopathology, and/or peripheral blood smear evaluation. All animal
studies were approved by the Institutional Animal Care and Use Committee of the University of
New Hampshire.

Ceramide Nanoliposome formulation and treatment
Lip-C6 and Lip-Ghost were generously prepared and provided by Dr. Mark Kester of the
University of Virginia. Briefly, lipids dissolved in chloroform, were combined in specific molar
ratios, dried to a film under nitrogen, and then hydrated by addition of 0.9% NaCl. Solutions
were sealed, heated at 60°C for 60 minutes, subjected to vortex mixing, and sonicated until light
no longer diffracted through the suspensions. Lipid vesicle-containing solutions were then
extruded at 60°C by passing the solutions 10 times through 100 nm polycarbonate filters using
an Avanti Mini-Extruder (Avanti Polar Lipids, Alabaster, AL). Size and charge were validated
using a Malvern Zetasizer Nano ZS at 25°C, and C6-ceramide encapsulation into anionic
formulations was quantified by mass spectroscopy. Liposomal suspensions were stored at room
temperature until use.
Therapeutic efficacy of Lip-C6, Lip-Ghost, or recombinant GDF1 as a standalone
treatments were evaluated using transgenic mouse models. 4–8-month-old (male and female)
Nup98-HoxD13 transgenic mice were injected with Lip-C6 (11.6 mg/kg), Lip-Ghost (volume
matched), or recombinant GDF1 (2 µg/kg) daily for 10 days. One day after the final injection,
mice were euthanized and bone marrow was collected from femurs and tibias, spleens were
removed and measured, and blood was collected by cardiac puncture for blood smears.
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Recombinant GDF1 formulation and treatment
Recombinant human GDF1 was purchased from R&D Systems. It arrived in a lyophilized
form with BSA as a carrier protein and was re-suspended according to the manufacture’s
direction. Therapeutic efficacy of recombinant GDF1 as a standalone treatment was evaluated in
vitro with colony-forming assays using bone marrow from FLT3ITD transgenic or C57BL/6J
wildtype mice as described below. In addition, therapeutic efficacy of recombinant GDF1 as a
standalone treatment was evaluated in vivo using Nup98-HoxD13 transgenic mice as described
above. Lastly, therapeutic efficacy of recombinant GDF1 in combination with AraC was
evaluated using 4–8-month-old (male and female) C1498-engrafted wildtype mice. Mice were
treated with recombinant GDF1 (2 µg/kg) +/- AraC (50 ng/kg), three times per week for two
weeks and survival was monitored.

Colony-forming assays
Murine bone marrow mononuclear cells were isolated and prepared from transgenic mice
and their wildtype counterparts and cleaned of debris using Ficoll-Paque PLUS (GE Healthcare
Life Sciences) density gradient centrifugation. Prior to colony-forming assays, leukemia was
confirmed by the investigative team and the NHVDL in transgenic mice based on spleen or bone
marrow histopathology, and/or peripheral blood smear evaluation. Murine samples were cultured
in triplicate in 12-well plates at a density of 2.5 x 104 cells per well in Murine MethoCult GF
(#M3434) (StemCell Technologies, Vancouver, BC). The plating density was selected to yield
typical wildtype or transgenic mouse colony out-growth of ~30-150 colonies per well in the
absence of drug treatment. Sterile water was added into empty wells, and space between wells, to
maintain optimal humidity necessary for colony growth. During assay set-up, murine bone
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marrow cells were added simultaneously to the culture media with recombinant GDF1 (200
ug/ml) or controls. The cultures were mixed vigorously and then dispensed to multi-well plates
and incubated for 10-14 days. Blinded investigators manually counted each type of colonies and
total colonies, including blast or miscellaneous colonies. Other types of colonies counted were
CFU-E, BFU-E, CFU-G, CFU-M, CFU-GM, and CFU-GEMM colonies.

Flow cytometry
Isolated bone marrow cells from transgenic mice were prepared and stained with Mouse
Fc Block, fluorophore-conjugated anti-mouse Gr-1 (clone RB6-8C5), fluorophore-conjugated
anti-mouse CD11b (clone M1/70), fluorophore-conjugated anti-mouse CD117 (clone 2B8),
fluorophore-conjugated anti-mouse CD71 (clone C2), and fluorophore-conjugated anti-mouse
TER-119/LY-76 (clone TER-119) monoclonal antibodies from BD Biosciences (San Jose, CA).
Gr-1+ CD11b+ cells were evaluated and quantified as representative of leukemia burden
(immature myeloid cells). CD117- CD71+ Ter119+ cells were evaluated and quantified as
representative of erythroid cells. Flow cytometry was performed at the University of New
Hampshire’s University Instrumentation Center using a Sony SH800Z sorting flow cytometer.

Statistical analysis
GraphPad Prism (GraphPad Software, La Jolla, CA) was used to perform data analyses.
Comparisons of colony-forming and flow cytometry data were made using 1-way ANOVA
followed by a Tukey’s multiple comparisons test. The Mantel-Cox Logrank test was used to
determine survival significance between in vivo treatment groups.
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CHAPTER 46

OBESITY PROMOTES ACUTE MYELOID LEUKEMIA PROGRESSION BY
UPREGULATING THE CERAMIDE-MEDIATED NADPH OXIDASE 2

4.1. Abstract
Acute myeloid leukemia (AML) is a type of blood cancer of the myeloid cell lineage.
Obesity is characterized by an increase in body weight that results in excessive fat accumulation.
Obesity has been associated with an increased incidence of many cancers, including blood
cancers. This study evaluated the role obesity in AML progression in a novel transgenic mouse
model developed by crossing Flt3ITD mice with Lepob/ob mice. Leukemia burden was augmented
in obese AML mice. In addition, it was determined that obesity upregulated the ceramidemediated and ceramide-1-phosphate-mediated NADPH oxidase 2. Notably, increased oxidative
pathways has been attributed to disease progression in AML. Taken together, this study
demonstrates a direct link between obesity and the progression of AML in part by augmenting
the ceramide-mediated NADPH oxidase 2.

4.2. Introduction
Cancer is a group of diseases involving abnormal cell growth that has the potential to
invade into other parts of the body (Font-Burgada et al., 2016). Acute myeloid leukemia (AML)
is a type of blood cancer of the myeloid cell lineage. It most commonly occurs in older adults
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over 60 years old and accounts for the largest number of annual deaths from leukemia in the
United States (O’Donnell et al., 2013). In recent years, obesity has been found to be an important
risk factor for the development of cancer, including blood cancers. Obesity can promote the
progression of cancer through several systemic mechanisms, such as causing chronic
inflammation; producing excess amounts of estrogen, insulin, adipokines; as well as changing
the mechanical properties of the scaffolding surrounding cancer cells (Gallagher and LeRoith,
2015; Gregor and Hotamisligil, 2011; Seo et al., 2015). Chronic inflammation takes place at
particular organ sites, including the liver, pancreas, and gastrointestinal tract (Font-Burgada et
al., 2016). Obesity-associated inflammation can dramatically alter tissue composition, thereby
creating a fertile environment for cancer development (Olson et al., 2017).
Sphingolipids are a class of lipids composed of sphingoid base and fatty acids with
ceramide being a hypothetical central metabolite. Sphingolipid metabolism is a complex network
of interconnected pathways. Sphingolipids are formed via the metabolism of sphingomyelin, a
constituent of the plasma membrane, through metabolism of other complex sphingolipids, or by
de novo synthesis. In addition to functioning as structural elements, sphingolipids also participate
in a variety of cellular pathways including apoptosis, cell senescence, the cell cycle, and cell
differentiation. Several sphingolipid mediators including ceramide and ceramide-1-phosphate
(C1P) have been found to play an integral role in inflammation (Nixon, 2009).
This research study evaluated a link between obesity and AML in a novel transgenic
mouse model. The impact of obesity on the progression of AML was further explored by
studying the expression of genes encoding sphingolipid-metabolizing enzymes involved in
inflammation and oxidative stress. Increased leukemia burden was observed in obese AML mice,
which also upregulated inflammatory sphingolipid metabolism and the NADPH oxidase 2.
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4.3. Results
Initially, a transgenic obese AML mouse model was developed by crossing the Flt3ITD
and Lepob/ob mice. The Lepob/ob mouse is a mjaor model of obesity that arises due to a
spontaneous mutation in the gene encoding the hormone leptin (Lutz and Woods, 2012). Leptin
is produced predominantly by adipocytes (Mohamed-Ali et al., 1998). It helps regulate energy
balance by inhibiting hunger and diminishing fat storage in adipocytes. In obesity, the body
develops insensitivity to leptin, thus is unable to detect satiety (Pan et al., 2014). Homozygous
leptin-deficient mice are phenotypically indistinguishable from their unaffected littermates at
birth, but gain weight rapidly throughout their lives, reaching a weight over twice that of
unaffected mice. The Flt3ITD transgenic mouse is a model where a myeloproliferative neoplasm
evolves to AML. FMS-like tyrosine kinase-3 (FLT3) is a receptor tyrosine kinase and protooncogene involved in crucial steps of hematopoiesis such as proliferation, differentiation and
survival. The FLT3ITD mutation has been strongly associated with oor prognosis, leukocytosis,
high blast counts, increased risk of relapse and shorter overall survival of AML patients
(Lagunas-Rangel and Chávez-Valencia, 2017). These two mouse models were crossed to
develop the Flt3ITD x Lepob/ob mouse model to further study the role of obesity in AML
development and progression. Notably, the Flt3ITD x Lepob/ob mouse model had similar weight
gain as the Lepob/ob mouse model and they were indistinguishable in appearance (Figure 4.1). In
addition, peripheral blood smears demonstrated that the transgenic obese AML model (Flt3ITD x
Lepob/ob mice) developed a more robust leukemia as evidenced by the substantial appearance of
blasts as compared with the Flt3ITD transgenic AML mouse model (Figure 4.2).

123

Figure 4.1. Flt3ITD x Lepob/ob mice have similar weight gain as Lepob/ob mice. An aged Flt3ITD x Lepob/ob
mouse (A) and an aged Lepob/ob mouse (B) are demonstrated visually. Weight gain patterns of Flt3ITD x
Lepob/ob mice (C) and Lepob/ob mice (D). As the age of these transgenic mice approaches 160 days, their
weight plateaus around 65 grams.
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Figure 4.2. Flt3ITD x Lepob/ob mice developed robust AML compared with Flt3ITD mice. A peripheral
blood smear from a wildtype mouse (A) displays all small, pink, and normal red blood cells, indicative of
normal and nonmalignant cells. Similarly, a peripheral blood smear from a Lepob/ob mouse (B) displays a
similar appearance, indicative that obese mice likewise do not have notable phenotypic changes in the
blood system. In contrast, a peripheral blood smear from a Flt3ITD mouse (C) displays a handful of blasts,
indicative that the mouse has leukemic transformation. Most notably, a peripheral blood smear from a
Flt3ITD x Lepob/ob mouse (D) shows considerably greater number of blasts than that of the Flt3ITD mouse
(C), indicative that the malignancy has more robustly developed.

The impact of obesity on ceramide metabolism and signaling in AML was next
investigated to further explore a possible mechanism where obesity can promote AML
progression. Obesity is known to induce several pathological conditions including insulin
resistance, in which glucose metabolism and ceramide metabolism play key pathological roles
(Longato et al., 2012). Obesity-driven increases in ceramide have been linked to glucose
intolerance (Turpin et al., 2014). Acid sphingomyelinase (SMPD1) is an enzyme that hydrolyzes
sphingomyelin to liberate ceramide, modulating membrane properties and signal transduction
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pathways including those mediated by inflammation (Gorelik et al., 2016). Ceramide kinase
(CERK) is a lipid kinase that is responsible for the phosphorylation of ceramide to ceramide-1phosphate (C1P) at the plasma membrane and in Golgi complex (Boath et al., 2008). NADPH
oxidase 2 is a superoxide generating enzyme. Superoxide is crucial in killing foreign bacteria in
the human body. Decreased activity of NADPH oxidase 2 can lead to an increased susceptibility
to organisms such as catalase-positive microbes, while its increased activity can lead to oxidative
stress (Fuentes et al. 2018). Both ceramide and C1P have been found to activate NADPH oxidase
2 to participate in redox-mediated signaling processes (Barth et al., 2012).
In the present study, obesity in the Flt3ITD x Lepob/ob mouse model was shown to lead to
aberrant gene expression involving aspects of sphingolipid metabolism and redox signaling,
reflected increased gene expression of Smpd1, Cerk, and Nox2 (encodes primary membranebound subunit of NADPH oxidase 2) (Figure 4.3). Collective upregulation of these genes enables
the ceramide-mediated NADPH oxidase 2 (Figure 4.4), where inflammatory stress can provoke
ceramide and C1P generation that promotes activation of NADPH oxidase 2. Activation of this
pathway would enable redox-mediated progression of AML, similar as observed in the Flt3ITD x
Lepob/ob obese AML transgenic mouse model.
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Figure 4.3. Smpd1, Cerk, and Nox2 are upregulated in Flt3ITD x Lepob/ob mice. Bone marrow from agematched wildtype, Lepob/ob, Flt3ITD, and Flt3ITD x Lepob/b mice was harvested and analyzed by RT-qPCR
(wildtype mice were used as a fully-normal control). Expression of Smpd1, Cerk, and Nox2 was elevated
in all mice and was highest in the Flt3ITD x Lepob/b obese AML mouse model. n=3 per mouse.

Figure 4.4. Schematic diagram of the ceramide- and C1P-mediated NADPH oxidase 2. Acid
sphingomyelinase generates ceramide from sphingomyelin, including in response to obesity-driven
inflammation. Ceramide kinase coverts ceramide into ceramide-1-phosphate. Both ceramide and ceramide1-phosphate activate NADPH oxidase 2, which generates superoxide (O2-). Membrane subunits of NADPH
oxidase 2 include gp91phox and p22phox. Cytosolic subunits of NADPH oxidase 2 include p47phox, p67phox,
p40phox, and Rac1/2.
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4.4. Discussion
Obesity is an important risk factor for the development of cancer, although the
relationship is not as clear as that between tobacco use and lung cancer (Zitvogel et al., 2017).
Nearly 25% of the relative contribution to cancer has since been ascribed to being overweight
and obese (Nimptsch and Pischon, 2016). It is widely agreed that obesity promotes both primary
tumor growth and metastatic progression through several systemic mechanisms (Olson et al.,
2017). In particular, obesity-associated oxidative stress has been found to cause genetic damage,
facilitating the transformation of premalignant cells (Manna and Jain, 2015). Moreover, NADPH
oxidase-dependent redox-signaling has been shown to promote proliferative signaling.
In this study, the role of obesity in the progression AML was evaluated in a novel
transgenic obese AML mouse model (Flt3ITD x Lepob/ob mice). Interestingly, these mice had
similar weight gains as their obese littermates but developed a more robust AML than non-obese
Flt3ITD transgenic AML mice, indicative that obesity augments the progression of AML.
Mechanistically, obesity upregulates the expression of genes encoding for the: 1) ceramidegenerating enzyme SMPD1, 2) C1P-generating enzyme CERK, and 3) primary membrane-bound
NADPH oxidase 2 subunit. Both ceramide and C1P can activate the NADPH oxidase 2 to
promote redox signaling and oxidative stress. Therefore, these results indicate that transgenic
obese AML mice have a high oxidative burden. By increasing oxidative stress and redoxsignaling within the AML cells obesity may accelerate the molecular evolution of AML
(Marseglia et al., 2014), as well as promote a more proliferative cellular state.
There are other mechanisms through which obesity can promote cancer progression. For
example, at a primary tumor site, obesity increases myofibroblast content, which stiffens
extracellular matrices and enhances cancer cell growth. Inflammasome activation in tumor-
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infiltrating myeloid cells has also been shown to drive increased IL-1b signaling in tumors. In
response, adipocytes express more VEGF-A, which increases tumor angiogenesis (Kolb et al.,
2016). Additionally, cholesterol metabolites have been shown to promote metastasis of cancer by
promoting the epithelial-mesenchymal transition (Nelson et al., 2013). Moreover, at the
metastatic site, IL5Ralpha+ monocytes generate GM-CSF and promote neutrophil expansion
(Quail et al., 2017). Circulating neutrophilia occurs in response to the increased GM-CSF and
can promote seeding and outgrowth of disseminated cancer cells (Olson et al., 2017).
Altogether, interventions are being investigated to mitigate the effects of obesity in
cancer. Caloric restriction is the most widely studied strategy. Caloric restriction has been found
to reverse breast inflammation associated with obesity in women (Bhardwaj et al., 2013).
Second, lifestyle interventions, such as exercise and fasting, have been found to improve immune
function in preclinical studies. Fasting increases the levels of lymphoid progenitor cells and
cytotoxic CD8+ lymphocytes, enhancing the targeted killing of cancer cells (Di Biase et al.,
2016). In conclusion, it is imperative to understand mechanisms by which obesity affects cancer
progression. In this way, better personalized approaches to treat obese cancer patients can be
developed.

4.5. Materials and methods
Animal studies
B6.129-Flt3tm1Dgg/J (Flt3ITD) transgenic mice develop a myeloproliferative neoplasm that
evolves to AML (Loghavi et al., 2014). FLT3 is a receptor tyrosine kinase. It is important for the
development of the hematopoietic and immune systems. The FLT3ITD mutation is one of the
most common molecular abnormality in acute myeloid leukemia (Levis and Small, 2003). Mice
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that are homozygous for this targeted mutation develop a progressive myeloproliferative disease,
exhibiting increased myeloid and monocytic cell populations and reduced B and T cell lymphoid
cell numbers. These FLT3-mutant transgenic mice were crossed with B6.Cg-Lepob/J (Lepob,
commonly referred to as ob or ob/ob) mice. Homozygous Lepob/ob mice have a spontaneous
mutation in the gene encoding for the hormone leptin, which normally regulates energy
homeostasis and appetite. These homozygous leptin-deficient mice exhibit obesity, hyperphagia,
transient hyperglycemia, glucose intolerance, and elevated plasma insulin. Therefore, crossing
FLT3-mutant mice with leptin-deficient mice resulted in a new transgenic mouse that develops
AML in the context of obesity.
Bone marrow cells were isolated from the femurs and tibias of 4–8-month-old (male and
female) transgenic mice and their respective wildtype littermates for RT-qPCR analysis. Mice
were submitted to the New Hampshire Veterinary Diagnostic Laboratory (NHVDL) at the
University of New Hampshire for histopathological evaluation. Leukemia was confirmed by the
investigative team and the NHVDL in transgenic mice based on spleen or bone marrow
histopathology, and/or peripheral blood smear evaluation. All animal studies were approved by
the Institutional Animal Care and Use Committee of the University of New Hampshire.

Peripheral blood smear preparation
Peripheral blood smears are prepared by placing a drop of blood on one end of a slide and
using a spreader slide to disperse the blood over the slide's length. The slide is left to air dry and
stained with Wright-Giesma stain to distinguish the cells from each other. The eosin Y dye stains
red blood cells a faint pink color, while the methylene blue and azure B dyes stains lymphocytes
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a purple-blue color (Schulte et al., 1989). The slide is left to air dry for roughly 24 hours before it
is observed under a light microscope.

RT-qPCR analysis
Total cellular RNA from mouse bone marrow samples was extracted and cleaned using
Zymo Research kits. RNA quality was evaluated using a NanoDrop 8000 spectrophotometer
(Thermo Fisher Scientific), and reverse transcribed with Taq polymerase to generate cDNA.
Quantitative polymerase chain reaction (qPCR) was performed using PrimeTime® Gene
Expression Master Mix (Integrated DNA Technologies) on a CFX96 Real-Time PCR System
(Biorad). Gene expression was determined using the 2–DDCt method using cycle threshold (Ct)
values for target genes as well as two endogenous reference genes (ACTB and TBP). Primer and
probe assays were obtained from Integrated DNA Technologies.

Statistical analysis
GraphPad Prism (GraphPad Software, La Jolla, CA) was used to perform data analyses.
Comparisons of RT-qPCR data were made using student’s t-tests as well as 1-way ANOVA
followed by a Tukey’s multiple comparisons test.
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CHAPTER 5

CONCLUSIONS AND FUTURE PERSPECTIVES

5.1. General Conclusions
Growth/differentiation factor 1 (GDF1) is transcribed from a bicistronic gene and can
engage transforming growth factor beta receptor 1 (TGFβR1) to mediate cellular effects
including regulation of gene expression by the SMAD2/3 pathway. Currently, the understood
role of GDF1 is limited to left-right patterning, including during cardiac development, as well as
mesoderm induction during embryonic development. Little else is known about the role of
GDF1, especially outside of embryonic development, although many related members of the
transforming growth factor beta (TGFb) superfamily have been attributed roles in stem cell
biology. Previously, nanoliposomal C6-ceramide (Lip-C6) was shown to exert preclinical
therapeutic efficacy in acute myeloid leukemia (AML) with myelodysplastic syndrome (MDS)related changes (AML-MRC) whereas other types of AML were resistant due to enhanced
ceramide metabolism. Intriguingly, GDF1 expression is likewise low in these Lip-C6-resistant
AMLs. Therefore, it was postulated that GDF1 may have anti-AML therapeutic efficacy due to
an ability to regulate ceramide metabolism.
In the first research study (Chapter 2), GDF1 was observed to be variably expressed in
AML, and mostly downregulated in Lip-C6-resistant AML. More so, it was shown that GDF1
downregulated the expression of UGCG and SGMS1, both of which encode enzymes that
metabolize ceramide into non-toxic sphingolipids. Lastly, GDF1 was observed to uniquely
promote SMAD2/3 phosphorylation while downregulating STAT3 tyrosine phosphorylation,
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both in a TGFβR1-dependent manner. In the second research study (Chapter 3), it was found that
recombinant GDF1 promotes hematopoiesis by decreasing immature myeloid cells while
increasing the maturation of monocytes and erythrocytes. Moreover, it was found that
recombinant GDF1 exerted combinatorial anti-AML efficacy with cytarabine (AraC).
Collectively, the studies reported in Chapters 2 and 3 demonstrate an anti-AML effect for GDF1
that is inherently linked to its ability to regulate ceramide metabolism. In the final research study
(Chapter 4), a transgenic obese AML mouse model was developed to study links between
obesity and the development and progression of AML. These obese AML mice develop a more
robust AML than non-obese counterparts and upregulate elements of the ceramide-mediated
NADPH oxidase 2. In that way, obesity can activate a sphingolipid-mediated pathway that is
responsive to obesity-driven inflammation to augment AML development and progression.

5.2. Future Directions
In the future, drug discovery efforts are planned to uncover compounds that regulate
ceramide metabolism including regulators of GDF1. These studies are further planned to
evaluate anti-AML therapeutic efficacy in combination with ceramide-based therapeutics such as
Lip-C6. Previous studies have demonstrated an anti-AML therapeutic ability of bioactive
compounds found in a plant called Devil’s Club (Oplopanax horridus). This is a medicinal plant
used among indigenous people of Southeast and Southcentral Alaska and the coastal Pacific
Northwest. Future studies are planned to extract bioactive compounds of Devil’s Club, and other
medicinal plants, to uncover compounds that can regulate ceramide metabolism, GDF1, as well
as exert anti-AML efficacy. This will shed more light on the potential of medicinal plants for the
development of novel AML therapeutics.
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